[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4914
1. Tomaru A, Kawachi M, Demura M, Fukuyo Y: Denaturing gradient gel electrophoresis shows that bacterial communities change with mid-ocean ballast water exchange. Mar Pollut Bull; 2010 Feb;60(2):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denaturing gradient gel electrophoresis shows that bacterial communities change with mid-ocean ballast water exchange.
  • Ships carry ballast water for better stability and to control trim.
  • However, the discharge of ballast water near ports is known to transport invasive species from one coastal area to another.
  • The exchange of ballast water on the high seas is supposed to reduce such invasions of exotic species.
  • In this study, we used denaturing gradient gel electrophoresis (DGGE) to analyze the composition of the bacterial community in ballast water before and after such a mid-ocean exchange, and we also measured total bacterial counts.
  • Our findings confirmed that the ballast water was replaced by the mid-ocean exchange, as indicated by the marked change in the composition of the bacterial community.
  • There was also a significant decrease in bacterial abundance after the mid-ocean exchange.
  • Finally, our findings support the incubation hypothesis, because the composition of the bacterial communities changed over time within the same ballast water.
  • [MeSH-major] Bacterial Physiological Phenomena. Ecosystem. Electrophoresis, Polyacrylamide Gel. Seawater / microbiology. Ships
  • [MeSH-minor] Bacteria / genetics. Bacteria / growth & development. Colony Count, Microbial. Oceans and Seas. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20022346.001).
  • [ISSN] 1879-3363
  • [Journal-full-title] Marine pollution bulletin
  • [ISO-abbreviation] Mar. Pollut. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


2. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual histological variants of prostatic carcinoma: clinical significance.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • These variants are rare and account for 5-10% of carcinomas that originate in the prostate.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


3. Papadopoulos O, Kostopoulos E, Karypidis D, Tsantoulas Z, Moustaki M: Review of nasal reconstruction. J Craniofac Surg; 2009 Jul;20(4):1072-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were analyzed in relation to their age, sex, location of the defect, histologic diagnosis of the lesion, type of reconstruction, recurrence of the tumor, and final outcome.
  • Basal cell carcinoma was the most common type, affecting 1399 patients (87.8%), followed by squamous cell carcinoma, which was identified in 109 patients (6.8%).
  • Cutaneous melanoma was not a frequent diagnosis.
  • Efficient diagnosis and appropriate reconstruction are prerequisites for the final desired outcome.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506524.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Zalaudek I, Argenziano G, Soyer HP, Corona R, Sera F, Blum A, Braun RP, Cabo H, Ferrara G, Kopf AW, Langford D, Menzies SW, Pellacani G, Peris K, Seidenari S, DERMOSCOPY WORKING GROUP: Three-point checklist of dermoscopy: an open internet study. Br J Dermatol; 2006 Mar;154(3):431-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a pilot study, the three-point checklist of dermoscopy has been shown to represent a valid and reproducible tool with high sensitivity for the diagnosis of skin cancer in the hands of a small group of nonexperts.
  • OBJECTIVES: To re-evaluate these preliminary results in a large number of observers independently from their profession and expertise in dermoscopy.
  • After a short web-based tutorial, the participants evaluated dermoscopic images of 165 (116 benign and 49 malignant) skin lesions (15 training and 150 test lesions).
  • Sensitivity for skin cancer (melanoma and basal cell carcinoma) was 91.0% and this value remained basically uninfluenced by the observers' professional profile.
  • CONCLUSIONS: Our study confirms that the three-point checklist is a feasible, simple, accurate and reproducible skin cancer screening tool.
  • [MeSH-major] Dermoscopy / standards. Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Clinical Competence. Diagnosis, Differential. Humans. Internet. Melanoma / diagnosis. Melanoma / pathology. Observer Variation. Sensitivity and Specificity. Skin Diseases / diagnosis. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445771.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


5. Nan H, Qureshi AA, Hunter DJ, Han J: A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control; 2009 Mar;20(2):171-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
  • We evaluated the effect of MDM2 SNP309 and its interaction with the p53 Arg72Pro polymorphism on pigmentary phenotypes and skin cancer risk in a nested case-control study within the Nurses' Health Study (NHS) among 219 melanoma cases, 286 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 873 controls, and among controls from other studies.
  • We found that the G allele of the MDM2 SNP309 was inversely associated with the presence/absence of moles on the arm among 3,207 women pooled from controls of three nested case-control studies within the NHS.
  • No significant associations were found between the MDM2 SNP309 and any of the three types of skin cancer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):72-7 [10625176.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1605-9 [10789732.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2000 Oct;16(5):195-201 [11068857.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1550-1 [11115171.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):513-9 [12394194.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):311-5 [12893080.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):760-2 [15373782.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):724-33 [6358278.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):857-60 [8479525.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2258-62 [8182158.001]
  • [Cites] BMJ. 1995 Apr 8;310(6984):912-6 [7719184.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2445-9 [8570197.001]
  • [Cites] Nat Med. 1996 Aug;2(8):912-7 [8705862.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):245-51 [9119548.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1123-8 [9070662.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):410-4 [9351343.001]
  • [Cites] Oncogene. 1998 Nov 12;17(19):2543-7 [9824166.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1092-100 [9891044.001]
  • [Cites] Oncogene. 1999 Feb 18;18(7):1419-34 [10050879.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Feb;5(1):3-8 [15720184.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Aug;37(8):1547-53 [15896663.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1252-8 [16354196.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2608-15 [16510579.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):195-7 [16239061.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4867-71 [16914573.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1976-84 [16721784.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1514-21 [16943234.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):660-4 [17123590.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):621-5 [17387621.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):375-7 [17553029.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2262-7 [17827408.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):314-21 [18510673.001]
  • (PMID = 18814047.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122838-01A2; United States / NCI NIH HHS / CA / R01 CA122838; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / R03 CA128080; United States / NCI NIH HHS / CA / CA122838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS70183; NLM/ PMC2631619
  •  go-up   go-down


6. Forman SB, Ferringer TC, Garrett AB: Basal cell carcinoma of the nail unit. J Am Acad Dermatol; 2007 May;56(5):811-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nail unit.
  • We report a case of a 70-year-old white male with a basal cell carcinoma of the left thumb nail unit.
  • The defect was repaired with a full thickness skin graft.
  • Prior to this report, 21 cases of basal cell carcinoma have been reported in the world literature.
  • This case, as well as the prior reports, are reviewed with a focus on time to diagnosis, location, excisional technique, and method of repair.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437888.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Leonardi R, Matthews JB, Caltabiano R, Greco M, Lombardo C, Loreto C, Santarelli A, Lo Muzio L: MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts. Oral Dis; 2010 Nov;16(8):795-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the matrix metalloproteinase (MMP)-13 expression in associated and non-nevoid basal cell carcinoma syndrome (NBCCS) Odontogenic Keratocysts (OCKs) in order to contribute to a better understanding of the differences in the growth pattern between them.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Matrix Metalloproteinase 13 / analysis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20561220.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.4.24.- / MMP13 protein, human; EC 3.4.24.- / Matrix Metalloproteinase 13
  •  go-up   go-down


8. van Coppenraet LS, Smit VT, Templeton KE, Claas EC, Kuijper EJ: Application of real-time PCR to recognize atypical mycobacteria in archival skin biopsies: high prevalence of Mycobacterium haemophilum. Diagn Mol Pathol; 2007 Jun;16(2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of real-time PCR to recognize atypical mycobacteria in archival skin biopsies: high prevalence of Mycobacterium haemophilum.
  • Atypical mycobacterial skin infections are difficult to diagnose owing to their aspecific histopathologic presentations and to the presence of few bacteria.
  • The aim of this study was to investigate the incidence of mycobacterial involvement in skin biopsies showing granulomatous inflammation, using real-time polymerase chain reaction (PCR).
  • Real-time PCR specific for the genus Mycobacterium and the species Mycobacterium avium and Mycobacterium haemophilum was performed on formalin-fixed/paraffin-embedded biopsies from patients with granulomatous inflammation of the skin, from the period 1984 to 2004.
  • A control group was assembled from patients with proven basal cell carcinoma.
  • Of 30 patients, 13 (43%) were found to be positive for mycobacterial infection, of whom only 5 patients had been previously diagnosed with a mycobacterial disease. M. haemophilum was identified as the most common species (n=7).
  • The results show that real-time PCR is useful in detecting mycobacterial infections in undiagnosed formalin-fixed/paraffin-embedded skin samples and that the application of molecular approaches would improve the diagnoses of mycobacterial skin infections.
  • [MeSH-major] Mycobacterium Infections, Nontuberculous / diagnosis. Mycobacterium haemophilum / isolation & purification. Nontuberculous Mycobacteria / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction / methods. Skin Diseases, Infectious / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Databases, Factual. Female. Humans. Male. Middle Aged. Mycobacterium avium Complex / genetics. Mycobacterium avium Complex / isolation & purification. Mycobacterium avium-intracellulare Infection / diagnosis. Mycobacterium avium-intracellulare Infection / microbiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525676.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Mariolis-Sapsakos T, Theodoropoulos G, Flessas II, Orfanos F, Orfanos N, Konstantinou EA, Zagouri F, Vlachodimitropoulos D, Zografos GC: Lobular breast cancer in men: case report and review of the literature. Onkologie; 2010;33(12):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular breast cancer in men: case report and review of the literature.
  • BACKGROUND: Lobular breast cancer in men is an extremely infrequent occurrence due to the lack of lobules and acini in the male breast.
  • Such a rare case is described here.
  • CASE REPORT: A 74-year-old patient presented with a sizeable lesion in the right breast, which proved to be a lobular carcinoma.
  • This case represented a lobular carcinoma in a genotypically male patient under no exogenous or endogenous estrogenic influence.
  • CONCLUSIONS: The increasing number of male lobular breast cancer cases should be explored more extensively with particular emphasis placed on causally related genetic and hormonal factors.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Karyotyping. Male. Mastectomy, Modified Radical. Neoplasm Invasiveness. Neoplasm Staging


10. Della Puppa A, Dal Pos S, Zovato S, Orvieto E, Ciccarino P, Manara R, Zustovich F, Berti F, Gardiman MP, Scienza R: Solitary intra-ventricular brain metastasis from a breast carcinoma. J Neurooncol; 2010 Mar;97(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intra-ventricular brain metastasis from a breast carcinoma.
  • Prevalence of symptomatic central nervous system (CNS) metastases among patients with breast cancer ranges from 5% to 16%, although autoptic studies have reported prevalence rates of up to 30%.
  • Descriptions of solitary intra-ventricular metastasis are very rare; to date no cases from breast cancer have been reported in the literature.
  • We present the unusual case of a breast cancer patient who developed a solitary choroid plexus metastasis in the left lateral ventricle.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / pathology. Lateral Ventricles / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1999 Apr;27(4):359-63 [10347852.001]
  • [Cites] J Neurooncol. 1999;45(3):237-40 [10845394.001]
  • [Cites] South Med J. 1998 Dec;91(12 ):1159-62 [9853731.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1475-8 [15956518.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12 ):916-9 [9465591.001]
  • [Cites] Neurol India. 2008 Apr-Jun;56(2):179-81 [18688144.001]
  • [Cites] Magn Reson Med Sci. 2003 Oct 1;2(3):155-8 [16222108.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):521-3 [15177398.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):506 [10701550.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):157-60 [15690132.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):47-52 [8699225.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):594-7 [18313927.001]
  • (PMID = 19727563.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Cheng NX, Liu LG, Hui L, Chen YL, Xu SL: Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection. Aesthetic Plast Surg; 2009 Jul;33(4):563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection.
  • This report presents two cases of breast cancer occurring after injection of PAAG in augmented breasts.
  • The delayed diagnosis and more aggressive disease due to PAAG injection should be cause for concern.
  • It is very important to detect breast cancer early when it is covered by the induration of the injected gel and inflammation reaction after PAAG injection.
  • PAAG injection for augmentation mammaplasty may affect the outcome of breast cancer diagnosis and prognosis.
  • [MeSH-major] Acrylic Resins / administration & dosage. Acrylic Resins / adverse effects. Breast Neoplasms / chemically induced. Gels / administration & dosage. Gels / adverse effects. Mammaplasty / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156460.001).
  • [ISSN] 1432-5241
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Gels; 0 / polyacrylamide gels
  •  go-up   go-down


12. Skaria AM: Electrocoagulation and hazardous damage to a dental prosthesis. J Am Acad Dermatol; 2006 Mar;54(3):543-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of 50-year-old patient who experienced minor damage to a dental prosthesis after undergoing bipolar electrocoagualtion during micrographic surgery for scirrhous basal cell carcinoma of the cheek.
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Humans. Male. Middle Aged


13. Carneiro RC, de Macedo EM, Matayoshi S: Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):100-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma.
  • PURPOSE: The objective of this pilot study was to evaluate the efficacy and safety of 5% imiquimod cream in the treatment of periocular basal cell carcinoma (BCC) through the analysis of a case series.
  • METHODS: Eight subjects with primary nodular BCC of the eyelid were recruited.
  • RESULTS: Of a total of 10 lesions, 80% resolved clinically and histologically and have remained asymptomatic since.
  • CONCLUSION: Imiquimod cream 5% was shown to be an attractive alternative to surgical treatment of periocular BCC.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Eyelid Neoplasms / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthal Plast Reconstr Surg. 2011 Jul-Aug;27(4):305; author reply 305-6 [20966793.001]
  • (PMID = 20305508.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


14. Upjohn E, Braue A, Ryan A: Primary cutaneous carcinosarcoma: dermoscopic and immunohistochemical features. Australas J Dermatol; 2010 Feb;51(1):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An excisional biopsy was carried out and histology showed a biphasic tumour with a basal cell carcinoma like epithelial component and a dermal undifferentiated sarcoma, with pleomorphic spindle cells and numerous osteoclast-like giant cells.
  • Based on immunohistochemistry findings, a diagnosis of primary cutaneous carcinosarcoma was made and the patient underwent wide local excision.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinosarcoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148837.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Xiong H, van der Lelie D, Gang O: Phase behavior of nanoparticles assembled by DNA linkers. Phys Rev Lett; 2009 Jan 9;102(1):015504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The formation of a crystalline bcc phase was observed for a limited range of linker lengths, while the number of linkers per particle controlled the onset of system crystallization.

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257208.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Single-Stranded; 7440-57-5 / Gold
  •  go-up   go-down


16. Alves R, Ocaña J, Vale E, Correia S, Viana I, Bordalo O: Basal cell carcinoma and atypical fibroxanthoma: an unusual collision tumor. J Am Acad Dermatol; 2010 Sep;63(3):e74-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and atypical fibroxanthoma: an unusual collision tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dermoscopy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Rare Diseases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20708468.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


17. Lee HY, Na YR, Seok SH, Baek MW, Kim DJ, Park SH, Lee HK, Lee BH, Park JH: Spontaneous basal cell carcinoma in a 7-week-old Sprague-Dawley rat. Vet Pathol; 2010 Jan;47(1):137-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous basal cell carcinoma in a 7-week-old Sprague-Dawley rat.
  • Spontaneous basal cell carcinoma (BCC) is very rare in rats, with an incidence rate of only 0.14% reported in aged animals.
  • A spontaneous BCC occurred in a 7-week-old Sprague-Dawley rat housed in a specific-pathogen-free animal facility.
  • Immunohistochemically, cytokeratin 14 (an indicator for basal keratinocytes of the epidermis) showed strong reactions throughout the whole tumor, and cytokeratin 18 showed weak but positive reaction in the majority of nested tumor cells.
  • To the authors' knowledge, this is the first report of spontaneous BCC occurrence in young Sprague-Dawley rats.
  • [MeSH-major] Carcinoma, Basal Cell / veterinary. Rodent Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20080494.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-14
  •  go-up   go-down


18. Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, Szakály P, Wéber G, Horváth OP, Ferencz A: [Clinical study of non-melanoma skin cancer following human organ transplantation]. Magy Seb; 2010 Apr;63(2):84-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of non-melanoma skin cancer following human organ transplantation].
  • INTRODUCTION: Increasing evidence suggests that non-melanoma skin cancers (NMSC) are the most frequent tumours in transplanted patients.
  • PATIENTS AND METHODS: 116 adult, "Caucasian" (white skin) transplanted (kidney, simultaneous-pancreas-kidney) patients (70 male and 46 female) of the Surgical Department of Pécs University were enrolled from September 2008.
  • All patients underwent a a full skin examination by a dermatologist for NMSC as well as a standardized questionnaire was filled in to assess risk factors.
  • Histology showed 13 basal cell carcinoma (BBC), 3 squamous cell carcinoma (SCC), with a 4 : 1 ratio of BCC : SCC.
  • CONCLUSIONS: These data confirm the importance of skin cancer surveillance in transplant recipients via a close cooperation between Transplantation and Dermatological Centres.
  • Our results reflect the international data, except for the BCC : SCC ratio.
  • [MeSH-major] Head and Neck Neoplasms / etiology. Immunosuppressive Agents / adverse effects. Organ Transplantation / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Female. Hobbies. Humans. Incidence. Kidney Transplantation / adverse effects. Male. Middle Aged. Occupations. Pancreas Transplantation / adverse effects. Risk Factors. Sunburn / complications. Surveys and Questionnaires. Time Factors


19. Star WM, van't Veen AJ, Robinson DJ, Munte K, de Haas ER, Sterenborg HJ: Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol; 2006;86(5):412-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.
  • Photodynamic therapy (PDT) of superficial basal cell carcinoma using topical 5-aminolaevulinic acid (ALA) and 75-100 J/cm2 light dose yields unsatisfactory long-term results.
  • Fifteen patients with a total of 86 primary superficial basal cell carcinomas, received topical ALA and were illuminated 4 and 6 h later, both with 45 J/cm2 laser light (633+/-1 nm).
  • There was no correlation between protoporphyrin fluorescence and response, but a significant correlation between the percentage of fluorescence left after photobleaching by the first illumination and the amount of protoporphyrin re-synthesized 2 h later.
  • In conclusion, the long-term complete remission rate of fractionated ALA-mediated PDT of superficial basal cell carcinoma as reported here is significantly better than after PDT with single illumination previously reported by others, but equal to studies using single illumination with a much higher light fluence.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955185.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


20. Pan S, Dong Q, Sun LS, Li TJ: Mechanisms of inactivation of PTCH1 gene in nevoid basal cell carcinoma syndrome: modification of the two-hit hypothesis. Clin Cancer Res; 2010 Jan 15;16(2):442-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of inactivation of PTCH1 gene in nevoid basal cell carcinoma syndrome: modification of the two-hit hypothesis.
  • PURPOSE: PTCH1 has been identified as the gene responsible for nevoid basal cell carcinoma syndrome (NBCCS).
  • RESULTS: Although mutations and loss of heterozygosity of PTCH1 were frequently detected in both syndromic and nonsyndromic cases, hypermethylation of the PTCH1 promoter was not identified in the present series.
  • Of all the 44 cases examined, 13 were identified to fit the two-hit model, 14 to conform to a one-hit model, and the remaining 17 cases showing no alteration in PTCH1.
  • The distribution of two-hit, one-hit, and non-hit cases was significantly different between syndrome and nonsyndrome patients (P < 0.02).
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Carcinoma, Basal Cell / genetics. Gingival Neoplasms / genetics. Models, Genetic. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Child. Female. Gene Expression Regulation, Neoplastic. Gene Silencing / physiology. Genetic Predisposition to Disease. Humans. Loss of Heterozygosity. Male. Middle Aged. Mutation / physiology. Odontogenic Tumors / genetics. Odontogenic Tumors / pathology. Young Adult

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068110.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


21. Farley RL, Manolidis S, Ratner D: Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone. Dermatol Surg; 2006 Feb;32(2):307-15; discussion 315
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone.
  • Aggressive variants of basal cell carcinoma (BCC), such as infiltrating, morpheaform, and basosquamous types, are associated with invasion of underlying tissues and are often difficult to treat.1 BCCs located in embryonic fusion planes, such as the periauricular region, are thought to exhibit deep extension and, subsequently, high recurrence rates, although this theory has been challenged and remains controversial.2-4 Despite the known features of aggressive BCC, parotid gland invasion and temporal bone and facial nerve involvement are rarely reported occurrences.
  • We describe two patients with morpheaform BCC in the periauricular region demonstrating direct invasion of the parotid gland and concomitant facial nerve involvement.
  • These patients require complex surgical management, as highlighted in this report.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Nervous System Neoplasms / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Facial Nerve / pathology. Humans. Male. Neoplasm Invasiveness. Otorhinolaryngologic Surgical Procedures. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442061.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Jacobs RJ, Phillips G: Basal cell carcinoma mistaken for actinic keratosis. Clin Exp Optom; 2006 May;89(3):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma mistaken for actinic keratosis.
  • Increasing age and UV exposure are well-known associations with precancerous and cancerous skin lesions, including actinic (solar) keratosis, and squamous and basal cell carcinomata.
  • This report describes a patient with a facial skin lesion close to an eye that was initially believed to be actinic (solar) keratosis but was subsequently diagnosed as a basal cell carcinoma (BCC).
  • The diagnosis of BCC was helped pre-operatively by manipulation of the surrounding facial skin, which revealed the characteristic rolled edges and telangiectasis.
  • The lesion was surgically excised and the diagnosis of basal cell carcinoma was confirmed by pathological examination.
  • This patient illustrates the importance of careful observation and photo-documentation of suspicious skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Keratosis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Sunlight / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637973.001).
  • [ISSN] 0816-4622
  • [Journal-full-title] Clinical & experimental optometry
  • [ISO-abbreviation] Clin Exp Optom
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Ratanachomsri U, Sriprang R, Sornlek W, Buaban B, Champreda V, Tanapongpipat S, Eurwilaichitr L: Thermostable xylanase from Marasmius sp.: purification and characterization. J Biochem Mol Biol; 2006 Jan 31;39(1):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have screened 766 strains of fungi from the BIOTEC Culture Collection (BCC) for xylanases working in extreme pH and/or high temperature conditions, the so-called extreme xylanases.
  • [MeSH-minor] Enzyme Stability. Hydrogen-Ion Concentration. Substrate Specificity. Temperature. Xylans / metabolism

  • MedlinePlus Health Information. consumer health - Molds.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475280.001).
  • [ISSN] 1225-8687
  • [Journal-full-title] Journal of biochemistry and molecular biology
  • [ISO-abbreviation] J. Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Fungal Proteins; 0 / Xylans; EC 3.2.1.8 / Endo-1,4-beta Xylanases
  •  go-up   go-down


24. Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA: Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol; 2005 May;203(2):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines.
  • Constitutive activation of hedgehog signaling, often caused by PTCH1 inactivation and leading to inappropriate activation of GLI target genes, is crucial for the development of several human tumors including basal cell carcinoma of the skin and medulloblastoma.
  • The PTCH1 gene at 9q22 is also considered as a candidate tumor suppressor in transitional cell carcinoma (TCC), of which >50% show LOH in this region.
  • We have therefore investigated GLI-dependent promoter activity and expression of hedgehog pathway components in TCC cell lines and proliferating normal urothelial cells.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic / physiology. Signal Transduction / physiology. Trans-Activators / metabolism. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Genes, Tumor Suppressor. Hedgehog Proteins. Humans. Membrane Proteins / genetics. Membrane Proteins / metabolism. Promoter Regions, Genetic / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Veratrum Alkaloids / pharmacology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15521068.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  •  go-up   go-down


25. Fukuoka H, Moriuchi M, Yano H, Nagayasu T, Moriuchi H: No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer. J Med Virol; 2008 Aug;80(8):1447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer.
  • Mouse mammary tumor virus (MMTV) is the causative agent of breast tumors in mice.
  • Recently, DNA sequences homologous or closely related to MMTV env gene have been specifically detected in breast cancer tissue from significant numbers of American, Australian, and Tunisian women, suggesting a viral etiology for at least a part of human breast cancer.
  • However, the viral sequences have not been detected from any of breast cancer samples in several subsequent studies.
  • Thus, whether MMTV-related retrovirus is a causative agent of human breast cancer remains controversial.
  • To demonstrate if MMTV-related retrovirus is involved in Japanese cases of breast cancer, breast tissue specimens from 46 breast cancer patients and 3 patients with benign mammary tumors were investigated.
  • Thus, MMTV itself or MMTV-related retrovirus is not associated with breast carcinogenesis in Japanese women, and it is unclear whether this conclusion is merely a reflection of regional differences in its epidemics.
  • [MeSH-major] Breast Neoplasms. Gene Products, env / genetics. Genes, env. Mammary Tumor Virus, Mouse / isolation & purification
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / virology. Adult. Aged. Aged, 80 and over. Animals. Blotting, Southern. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / virology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / virology. Cell Line, Tumor. Female. Fibroadenoma / epidemiology. Fibroadenoma / genetics. Fibroadenoma / virology. Humans. Japan / epidemiology. Mice. Middle Aged. Nucleic Acid Hybridization. Phyllodes Tumor / epidemiology. Phyllodes Tumor / genetics. Phyllodes Tumor / virology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551605.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env
  •  go-up   go-down


26. Kiyici H, Bilezikçi B, Ozen O, Demirhan B: Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma. Pathol Res Pract; 2010 Jul 15;206(7):445-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma.
  • In this study, we evaluated the expression of Fragile Histidine Triad (FHIT) in basal cell carcinoma (BCC).
  • The FHIT locus was found to be altered in numerous types of cancer [6,7,18,20,22,25,26].
  • However, we found only one study dealing with FHIT expression in BCC [11].
  • In our study, we used immunohistochemical methods for the evaluation of FHIT expression in tissue samples of 42 BCC cases.
  • Ki-67 labeling index was used to compare cellular proliferation of BCC with internal and external controls.
  • As a primary result, there was no significant decrease in FHIT expression in early lesions of BCC.
  • As a second finding, there was no correlation between the intensity of FHIT staining and Ki-67 labeling index.
  • As a third finding, there was no difference in Ki-67 labeling index between early lesions of BCC and non-neoplastic epidermis.
  • We concluded that FHIT expression remains to be positive, at least in early lesions of BCC.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Carcinoma, Basal Cell / metabolism. Neoplasm Proteins / biosynthesis. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399571.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


27. de Koning MN, Quint WG, Pirog EC: Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. Mod Pathol; 2008 Mar;21(3):334-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma.
  • The goal of the study was to examine a possible role of cutaneous HPVs from the beta genus in vulvar carcinogenesis and to evaluate the distribution of intratypic variants of HPV 16 in HPV 16-positive vulvar cancer.
  • Consecutive cases of vulvar carcinoma were retrieved from the files and included the following histologic subtypes: keratinizing (n=21), basaloid (n=7), warty (n=1), mixed basaloid-warty (n=4), verrucous (n=4), keratoacanthoma (n=1), basal cell carcinoma (n=1).
  • Cases identified as positive for HPV 16 were further tested for intratypic variants.
  • All cases were immunostained for p16INK4a.
  • Beta HPVs were not detected in any of the tumor cases.
  • Mucosal HPVs were detected in all but one basaloid/warty carcinomas; of these, nine cases (82%) were positive for HPV 16, including five European subtypes, one African subtype, one North American subtype and two indeterminate subtypes.
  • Two of four verrucous carcinomas were positive for HPV 6.
  • Mucosal HPVs were not detected in keratinizing carcinomas, keratoacanthoma and basal cell carcinoma.
  • All cases of basaloid/warty carcinomas, but none of the remaining tumors, overexpressed p16INK4a protein.
  • Our data do not support a role of beta HPVs in the pathogenesis of vulvar carcinoma.
  • P16INK4a immunostaining seems to be a sensitive and specific marker of vulvar carcinomas positive for oncogenic mucosal HPvs.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Carcinoma, Verrucous / virology. Human papillomavirus 16 / isolation & purification. Papillomaviridae / isolation & purification. Vulvar Neoplasms / virology
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Female. Humans. Mucous Membrane / pathology. Mucous Membrane / virology. Oncogene Proteins, Viral / metabolism. Organ Specificity. Papillomavirus E7 Proteins. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Repressor Proteins / metabolism. Skin / pathology. Skin / virology. Tumor Virus Infections / metabolism. Tumor Virus Infections / pathology. Tumor Virus Infections / virology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192968.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


28. Phagoo SB, Reddi K, Silvallana BJ, Leeb-Lundberg LM, Warburton D: Infection-induced kinin B1 receptors in human pulmonary fibroblasts: role of intact pathogens and p38 mitogen-activated protein kinase-dependent signaling. J Pharmacol Exp Ther; 2005 Jun;313(3):1231-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kinin B(1) receptors (B(1)R) are involved in many pathophysiological processes, and its expression is up-regulated in inflammatory pulmonary disease.
  • The serious opportunistic clinical isolate Burkholderia cenocepacia (B. cen.) belongs to the important B. cepacia complex (Bcc) of gram-negative pathogens that rapidly causes fatal pulmonary disease in hospitalized and immunocompromised patients and those with cystic fibrosis.
  • The B(1)R response was dose-dependent and maximal by 6 to 8 h (3- to 4-fold increase), however, brief B. cen. infection could sustain B(1)R up-regulation.
  • In contrast, nonclinical Bcc phytopathogens were much less B(1)R inducive.
  • The protein synthesis inhibitor cycloheximide and transcriptional inhibitor actinomycin D abrogated the B(1) response to B. cen. indicating de novo B(1)R synthesis. B. cen. activated p38 mitogen-activated protein kinase (MAPK), and blocking p38 MAPK with the specific inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB 203580) dramatically reduced B. cen.
  • Furthermore, B. cen. regulation of B(1)R was diminished by the anti-inflammatory glucocorticoid dexamethasone.
  • In conclusion, this study is the first demonstration that infection with intact pulmonary pathogens like B. cen. positively modulates the selective expression of B(1)R.
  • Thus, providing evidence that B(1)R regulation may be an important and novel mechanism in the inflammatory cascade in response to chronic pulmonary infection and disease.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743925.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Bradykinin B1; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


29. Affleck AG, Gore A, Millard LG, Perks AG, Kulkarni K, Chan S: Giant primary basal cell carcinoma with fatal hepatic metastases. J Eur Acad Dermatol Venereol; 2007 Feb;21(2):262-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant primary basal cell carcinoma with fatal hepatic metastases.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Liver Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243972.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Rukachaisirikul V, Chantaruk S, Tansakul C, Saithong S, Chaicharernwimonkoon L, Pakawatchai C, Isaka M, Intereya K: A cyclopeptide from the Insect pathogenic fungus Cordyceps sp. BCC 1788. J Nat Prod; 2006 Feb;69(2):305-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cyclopeptide from the Insect pathogenic fungus Cordyceps sp. BCC 1788.
  • BCC 1788 along with four known bioxanthracenes (2-5).
  • [MeSH-minor] Animals. Artemisinins / pharmacology. Beetles. Cercopithecus aethiops. Chromatography, High Pressure Liquid. Crystallography, X-Ray. Inhibitory Concentration 50. Larva. Molecular Structure. Plasmodium falciparum / drug effects. Protein Conformation. Sesquiterpenes / pharmacology. Thailand. Vero Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499340.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Artemisinins; 0 / Peptides, Cyclic; 0 / Sesquiterpenes; 0 / cordyheptapeptide A; 6A9O50735X / dihydroartemisinin
  •  go-up   go-down


31. Soong TK, Soong V, Samsudin A, Soong F, Sharma V, O'Donnell N: Periocular dermatitis artefacta in a child. J AAPOS; 2006 Dec;10(6):585-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatitis artifacta is a factitious dermatological disorder with many forms of presentation in any part of the body.
  • It is commonly documented in dermatological cases but rarely presented as an ophthalmic condition.
  • The diagnosis of dermatitis artifacta is often concluded after rigorous and repeated investigation.
  • Histological sampling of skin lesions is usually required in these cases to exclude masquerading skin lesions such as basal cell carcinoma, vasculitis, or herpetic skin lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189158.001).
  • [ISSN] 1091-8531
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lynch KH, Dennis JJ: Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex. J Clin Microbiol; 2008 Feb;46(2):447-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex.
  • Burkholderia is an important bacterial genus with a complex taxonomy that contains species of both ecological and pathogenic importance, including nine closely related species collectively termed the Burkholderia cepacia complex (BCC).
  • Unfortunately, 16S rRNA gene analysis has proven to be not sensitive enough to discriminate between species of the BCC.
  • Alternative species identification strategies such as recA-based PCR followed by restriction fragment length polymorphism analysis, although initially useful, have proven to be inaccurate with the increasing species diversity of the BCC. recA gene sequence analysis is more discriminatory and corroborates other biochemical and polyphasic means of taxonomic differentiation.
  • However, it is limited by the fact that certain BCC species are subdivided into discrete recA sequence subgroups that may confuse clinical diagnoses.
  • In this study, an effective approach is described for the rapid differentiation of BCC species from both environmental and clinical sources by means of a single-locus sequencing and PCR assay using fur as a target gene that provides sequence phylogenies that are species specific and, with few exceptions, not divided into subspecies clusters.
  • This assay is specific and can be used to correctly determine the species status of BCC strains tested following sequencing and amplification of the fur gene by both general and species-specific primers.
  • This assay is useful for the rapid, definitive identification of all nine current BCC species and potentially novel species groups.
  • [MeSH-major] Bacterial Proteins / genetics. Burkholderia Infections / diagnosis. Burkholderia Infections / microbiology. Burkholderia cepacia complex / classification. Polymerase Chain Reaction / methods. Polymorphism, Genetic. Repressor Proteins / genetics

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):910-3 [10655415.001]
  • [Cites] J Clin Microbiol. 2007 Sep;45(9):3105-8 [17626169.001]
  • [Cites] Chest. 2000 Jun;117(6):1661-5 [10858399.001]
  • [Cites] J Clin Microbiol. 2000 Sep;38(9):3165-73 [10970351.001]
  • [Cites] J Clin Microbiol. 2001 Mar;39(3):990-4 [11230416.001]
  • [Cites] J Clin Microbiol. 2001 Mar;39(3):1073-8 [11230429.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3427-36 [11574551.001]
  • [Cites] Emerg Infect Dis. 2002 Feb;8(2):181-7 [11897071.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):309-11 [11919219.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3300-7 [12202570.001]
  • [Cites] Paediatr Respir Rev. 2002 Sep;3(3):230-5 [12376059.001]
  • [Cites] J Med Microbiol. 2002 Nov;51(11):937-40 [12448677.001]
  • [Cites] Res Microbiol. 2003 Mar;154(2):91-6 [12648723.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2797-8 [12791937.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jul 15;224(1):133-8 [12855180.001]
  • [Cites] Clin Microbiol Rev. 2004 Jan;17(1):57-71 [14726455.001]
  • [Cites] J Bacteriol. 2004 Sep;186(18):6015-24 [15342570.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Feb;80(3):726-30 [6572363.001]
  • [Cites] J Pediatr. 1984 Feb;104(2):206-10 [6420530.001]
  • [Cites] J Pediatr. 1986 May;108(5 Pt 2):830-4 [3701534.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Comput Appl Biosci. 1988 Mar;4(1):11-7 [3382986.001]
  • [Cites] Comput Appl Biosci. 1989 Apr;5(2):151-3 [2720464.001]
  • [Cites] Methods Enzymol. 1990;183:626-45 [2314296.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1007-17 [8629607.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):614-9 [9041399.001]
  • [Cites] Clin Chest Med. 1998 Sep;19(3):473-86, vi [9759550.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1197-205 [10191223.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3167-70 [10488171.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1193-201 [15746318.001]
  • [Cites] FEMS Microbiol Lett. 2005 May 1;246(1):39-45 [15869960.001]
  • [Cites] Appl Environ Microbiol. 2005 Jul;71(7):3917-27 [16000805.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4665-73 [16145124.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1920-6 [17460050.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1206-12 [10764313.001]
  • (PMID = 18057135.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU090823/ EU090824/ EU090825/ EU090826/ EU090827/ EU090828/ EU090829/ EU090830/ EU090831/ EU090832/ EU090833/ EU090834/ EU090835/ EU090836/ EU090837/ EU090838/ EU090839/ EU090840/ EU090841/ EU090842/ EU090843/ EU090844/ EU090845/ EU090846/ EU090847/ EU090848/ EU090849/ EU090850/ EU090851/ EU090852/ EU090853/ EU090854/ EU090855/ EU090856/ EU090857/ EU090858/ EU090859/ EU090860/ EU090861/ EU090862/ EU090863/ EU090864/ EU090865/ EU090866/ EU090867/ EU090868/ EU090869/ EU090870/ EU090871/ EU090872/ EU090873/ EU090874/ EU090875/ EU090876/ EU090877/ EU090878/ EU090879/ EU090880/ EU090881/ EU090882/ EU090883/ EU090884/ EU090885/ EU090886/ EU090887/ EU090888/ EU090889/ EU090890/ EU090891/ EU090892/ EU090893/ EU090894/ EU090895/ EU273473/ EU273474
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA Primers; 0 / DNA, Bacterial; 0 / Repressor Proteins; 0 / ferric uptake regulating proteins, bacterial
  • [Other-IDs] NLM/ PMC2238088
  •  go-up   go-down


33. Pope CF, Gillespie SH, Moore JE, McHugh TD: Approaches to measure the fitness of Burkholderia cepacia complex isolates. J Med Microbiol; 2010 Jun;59(Pt 6):679-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approaches to measure the fitness of Burkholderia cepacia complex isolates.
  • Members of the Burkholderia cepacia complex (Bcc) are highly resistant to many antibacterial agents and infection can be difficult to eradicate.
  • A coordinated approach has been used to measure the fitness of Bcc bacteria isolated from cystic fibrosis (CF) patients with chronic Bcc infection using methods relevant to Bcc growth and survival conditions.
  • We also describe a method to determine mutation rate in Bcc bacteria.
  • [MeSH-major] Burkholderia Infections / microbiology. Burkholderia cepacia complex / physiology. Cystic Fibrosis / complications. Microbial Viability

  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185551.001).
  • [ISSN] 1473-5644
  • [Journal-full-title] Journal of medical microbiology
  • [ISO-abbreviation] J. Med. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ903182/ FJ903183/ FJ903184/ FJ903185/ FJ903186/ FJ903187
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 5E8K9I0O4U / Ciprofloxacin; EC 5.99.1.3 / DNA Gyrase
  •  go-up   go-down


34. Mahajan SL, Sohal SP, Devgun P, Mahajan S, Mahajan S, Padda P: A study of frequency distribution and some epidemiological features of reported cases and deaths of dengue in Ludhiana district during the year 2008. J Commun Dis; 2010 Jun;42(2):139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of frequency distribution and some epidemiological features of reported cases and deaths of dengue in Ludhiana district during the year 2008.
  • There were 7337 cases and 50 deaths reported in the state of Punjab from 1997 to 2008 of which Ludhiana district of Punjab contributed 4973 cases and 32 deaths.
  • Number of cases (2506) and deaths (13) reported were highest in Ludhiana in the year 2008.
  • City/Area wise reporting of dengue cases in hospitals of Ludhiana in 2008 show that the disease is mostly prevalent in the urban areas but now has been reported from rural areas also as 2 cases have been reported from village Kumkalan, block Mangat, Ludhiana.
  • Age wise distribution of the cases shows maximum incidence per lakh population in 31-50 years (52.06) followed by 16-30 years (49.00) and lowest in infants (0.36).
  • Out of the 2988 cases reported from Ludhiana district, there were 1993 males, 989 females and no mention of the sex in 6 cases.
  • Month wise distribution of the cases shows maximum incidence per lakh population to be the highest in October (90.27) followed by November (33.39) and December (23.18).
  • As the dengue is increasingly becoming an escalating problem it needs necessary control measures especially regarding BCC activities and appointment of Biologists at the district level in Punjab needs to be done.

  • MedlinePlus Health Information. consumer health - Dengue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22471173.001).
  • [ISSN] 0019-5138
  • [Journal-full-title] The Journal of communicable diseases
  • [ISO-abbreviation] J Commun Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Nielsen KP, Juzeniene A, Juzenas P, Stamnes K, Stamnes JJ, Moan J: Choice of optimal wavelength for PDT: the significance of oxygen depletion. Photochem Photobiol; 2005 Sep-Oct;81(5):1190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To calculate efficiency spectra of PDT on human skin one needs to know the excitation spectrum of the photosensitizer of interest and the relative fluence rate as a function of depth in the tissue.
  • In this way we determined the efficiency spectra as functions of depth for different types of basal cell carcinomas (BCC).
  • Our results suggest that ALA-PDT works best for nodular BCC at a wavelength of 630 nm, whereas it works best for pigmented superficial BCC at a wavelength of 390 nm.
  • Below a 2 mm thick, well-oxygenated, nodular BCC, we find the efficiency to be an order of magnitude larger than below a poorly oxygenated tumor.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Light. Oxygen Consumption / physiology. Photochemotherapy / methods. Ultraviolet Rays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934793.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


36. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


37. Heppt W, Gubisch W: [Principles of nasal defect repair]. HNO; 2007 Jun;55(6):497-510
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The repair of nasal defects is a frequent challenge to facial plastic surgeons, mainly due to the high frequency of basal cell carcinomas.
  • These rules have to be modified for the nasal tip, the alar region, the columella and the vestibulum where free skin grafts and auricular composite grafts have to be considered.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Minimally Invasive Surgical Procedures / methods. Rhinoplasty / methods. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1999 Oct;104(5):1289-94 [10513908.001]
  • [Cites] Plast Reconstr Surg. 2002 May;109(6):1839-55; discussion 1856-61 [11994582.001]
  • [Cites] Plast Reconstr Surg. 1985 Nov;76(5):686-94 [4059408.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Scand J Plast Reconstr Surg. 1969;3(2):105-8 [4924039.001]
  • [Cites] Plast Reconstr Surg. 1967 Aug;40(2):147-9 [5340490.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):284-9 [10958513.001]
  • (PMID = 17486306.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


38. Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, Nelson HH: CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res; 2009 Aug 1;69(15):6158-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer.
  • Although skin tumors are highly immunogenic, exposure to UV radiation is known to suppress immune responses via regulatory T cells.
  • Specifically, the activity of cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is integral in regulating the development of UV-induced tolerance and, concomitantly, skin cancers.
  • Due to the inverse relationship between tumor surveillance and autoimmunity, we hypothesize that the same genetic variant in the CTLA4 locus that increases risk for autoimmune diseases is associated with decreased risk of non-melanoma skin cancer (NMSC).
  • We analyzed whether the polymorphism CT60 or haplotypes of CTLA4 influence odds of developing the major types of NMSC, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), in a population-based case-control study of Caucasians in New Hampshire (849 controls, 930 BCC, and 713 SCC).
  • The CTLA4 CT60 GG genotype was associated with decreased odds for BCC and SCC, controlling for age, sex, lifetime number of severe sunburns, and skin type [BCC: odds ratio (OR), 0.7; 95% confidence interval (95% CI), 0.5-0.9; SCC: OR, 0.7; 95% CI, 0.5-1.0].
  • For BCC, this decrease was apparent largely among those with a higher lifetime number of severe sunburns (P(interaction) = 0.0074).
  • There were significantly decreased odds of disease associated with two haplotypes, which possess the CT60 G allele.
  • Additionally, lifetime number of severe sunburns modestly altered the effects of the CTLA4 haplotypes in BCC, and the association seemed driven by the CT60 single nucleotide polymorphism.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1977 Jun 1;31(1):182-7 [872221.001]
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):211-5 [1003502.001]
  • [Cites] Immunology. 1981 Jul;43(3):527-33 [7251064.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):729-34 [1940446.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):911-3 [10359543.001]
  • [Cites] Annu Rev Immunol. 2005;23:515-48 [15771580.001]
  • [Cites] Immunol Rev. 2005 Apr;204:102-15 [15790353.001]
  • [Cites] Eur J Immunol. 2005 Jul;35(7):2157-62 [15940668.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Mar;165(2):114-20 [16527605.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3483-9 [16849765.001]
  • [Cites] Immunol Rev. 2006 Aug;212:131-48 [16903911.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1950-4 [18641401.001]
  • [Cites] Hum Immunol. 2007 Aug;68(8):698-704 [17678726.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6725-31 [10586070.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1824-31 [10925260.001]
  • [Cites] Nature. 2003 May 29;423(6939):506-11 [12724780.001]
  • [Cites] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281.001]
  • [Cites] Adv Exp Med Biol. 1976;66:445-9 [1266675.001]
  • [Cites] Cell Immunol. 1978 Jun;38(1):105-15 [667953.001]
  • (PMID = 19622768.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057494; United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / CA08235; United States / NCI NIH HHS / CA / R01 CA057494-16; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human
  • [Other-IDs] NLM/ NIHMS216796; NLM/ PMC2928067
  •  go-up   go-down


39. van der Pols JC, Heinen MM, Hughes MC, Ibiebele TI, Marks GC, Green AC: Serum antioxidants and skin cancer risk: an 8-year community-based follow-up study. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1167-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum antioxidants and skin cancer risk: an 8-year community-based follow-up study.
  • BACKGROUND: Antioxidant nutrients can help prevent skin damage caused by ultraviolet radiation from sunlight, but it is not clear whether serum concentrations of such nutrients influence skin cancer risk.
  • METHODS: We carried out a prospective study of the associations between serum concentrations of antioxidant nutrients and incidence (person-based and tumor-based) of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin among a random subsample of 485 adults from an Australian community.
  • Participants were divided into thirds, ranked according to their serum concentrations of carotenoids, alpha-tocopherol, and selenium measured in 1996 and were monitored for incident, histologically confirmed BCC and SCC tumors until 2004.
  • RESULTS: Although there were no associations between baseline serum carotenoids or alpha-tocopherol concentrations and incidence of BCC or SCC, baseline serum selenium concentrations showed strong inverse associations with both BCC and SCC tumor incidence.
  • Compared with participants with lowest selenium concentrations at baseline (0.4-1.0 micromol/L), those with the highest serum selenium concentrations (1.3-2.8 micromol/L) had a decreased incidence of BCC tumors (multivariate relative risk, 0.43; 95% confidence interval, 0.21-0.86; P(trend) = 0.02) and SCC tumors (multivariate relative risk, 0.36; 95% confidence interval, 0.15-0.82; P(trend) = 0.02).
  • CONCLUSION: Relatively high serum selenium concentrations are associated with an approximately 60% decrease in subsequent tumor incidence of both BCC and SCC, whereas serum concentrations of carotenoids or alpha-tocopherol are not associated with later skin cancer incidence.
  • A possible U-shaped association between serum selenium concentrations and SCC of the skin needs confirmation.
  • [MeSH-major] Antioxidants / metabolism. Biomarkers, Tumor / blood. Carotenoids / blood. Selenium Compounds / blood. Skin Neoplasms / epidemiology. alpha-Tocopherol / blood
  • [MeSH-minor] Aged. Australia / epidemiology. Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / epidemiology. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. VITAMIN E .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336544.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Selenium Compounds; 36-88-4 / Carotenoids; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


40. Knoop C, Estenne M: Disease-specific approach to lung transplantation. Curr Opin Organ Transplant; 2009 Oct;14(5):466-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-specific approach to lung transplantation.
  • PURPOSE OF REVIEW: The present review provides an update on the recent literature regarding disease-specific issues in lung transplantation.
  • Data from two large registry-based studies indicate that bilateral lung transplantation in patients with chronic obstructive pulmonary disease confers significantly longer survival than single lung transplantation, especially in patients younger than 60 years.
  • Mathematical models to estimate survival benefit in chronic obstructive pulmonary disease lung transplant candidates have been developed and are being validated.
  • The impact of Bcc colonization in cystic fibrosis patients on outcome has been nuanced; thus, cystic fibrosis lung transplant candidates colonized by particular Bcc strains may be transplanted with good outcomes.
  • SUMMARY: This article attempts to provide an overview of some of the currently important topics for clinicians involved in referring and evaluating patients with end-stage lung disease for lung transplantation in 2009.
  • [MeSH-major] Cystic Fibrosis / surgery. Lung Transplantation / methods. Patient Selection. Pulmonary Disease, Chronic Obstructive / surgery


41. Oda E, Nakamura Y, Yamamoto M, Kojiro M: Immunohistochemical distribution of tubulin beta II in human normal and neoplastic tissues. Kurume Med J; 2005;52(4):117-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We obtained normal tissues from 33 cases (8 fetuses, 17 neonates, 3 children and 5 adults) and 121 samples of neoplastic tissue from surgical specimens or at autopsy.
  • Tubulin beta II was detected in various normal tissues, particularly in fetal and neonatal tissues, such as the nervous system, pulmonary alveoli, bronchioles and bronchi, colon, pancreatic ducts and acini, renal convoluted tubuli, skin epidermis, body cavity mesothelial cells, smooth muscle and thymus.
  • In neoplastic tissues, tubulin beta II immunoreactivity was detected in various nervous system neoplasms and other neoplasms such as pancreatic solid cystic carcinoma, pleomorphic adenoma, Warthin's tumor, nephroblastoma, basal cell carcinoma and malignant mesothelioma.
  • We conclude that our monoclonal antibody, KNY379, may be useful as a marker of nervous system neoplasm, pancreatic solid cystic carcinoma, pleomorphic adenoma, Warthin's tumor, nephroblastoma, basal cell carcinoma and malignant mesothelioma.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639982.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / Tubulin
  •  go-up   go-down


42. Kovarik CL, Stewart D, Barnard JJ: Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol; 2005 Jan;52(1):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal basal cell carcinoma secondary to cerebral invasion.
  • Intracranial invasion by a basal cell carcinoma on the scalp is extremely rare.
  • We present an autopsy case of a 57-year-old woman who developed a large destructive basal cell carcinoma with extension through the calvarium and compression of the dura.
  • We compare 7 similar cases reported in the literature and review the risks for development of these aggressive fatal basal cell carcinomas on the scalp.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Autopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627099.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


43. Martorell-Calatayud A, Requena-Caballero C, Botella-Estrada R, Almenar-Medina S, Sanmartín-Jiménez O, Llombart-Cussac B, Nagore-Enguídanos E, Serra-Guillén C, Echeverría-García B, Guillén-Barona C: [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice]. Actas Dermosifiliogr; 2009 Oct;100(8):693-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice].
  • [Transliterated title] Carcinoma anexial microquístico: la cirugía micrográfica de Mohs como tratamiento de elección.
  • INTRODUCTION AND OBJECTIVES: Microcystic adnexal carcinoma is a rare and aggressive tumor that manifests clinically as a subcutaneous nodule located on the head or neck.
  • The tumor can be confused clinically and histologically with other benign and malignant skin lesions, often leading to inappropriate initial treatment.
  • The chief concern with microcystic adnexal carcinoma is the elevated morbidity and the high rate of recurrence after wide local excision.
  • MATERIAL AND METHODS: We reviewed the medical histories of 6 consecutive patients with microcystic adnexal carcinoma who underwent Mohs micrographic surgery in our dermatology department between 1995 and 2007.
  • RESULTS: In all cases, lesions were located on the head and were primary tumors.
  • Seventy percent of the tumors were wrongly diagnosed initially as basal cell carcinoma.
  • CONCLUSIONS: The absence of perineural involvement and substantial cell atypia can be attributed to the lesions being primary tumors.
  • The site and the absence of recurrence in all our patients who underwent Mohs micrographic surgery support the use of this technique as the treatment of choice in microcystic adnexal carcinoma.
  • [MeSH-major] Carcinoma / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775547.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. de Fijter JW: Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant; 2007 May;22 Suppl 1:i23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
  • Non-melanoma skin cancer (NMSC) affects a large proportion of renal transplant recipients, with estimates suggesting that at least half of white-skinned transplant recipients will develop NMSC following transplantation.
  • Squamous-cell carcinoma is the most frequent NMSC following transplantation occurring at a 100-times greater risk than in the general population, while the incidence of basal cell carcinoma is increased 10-fold over the general population.
  • The most important risk factor for the development of NMSC in renal transplant recipients is prior exposure to ultraviolet radiation, therefore, geographical location and skin type highly influence the risk of NMSC.
  • Given the potential anti-cancer actions of the proliferation signal inhibitors (PSIs), everolimus and sirolimus, demonstrated in both pre-clinical and clinical studies, we have analysed the effect of conversion to PSIs in 53 renal transplant recipients developing NMSC after transplantation.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Kidney Transplantation / adverse effects. Protein Kinases / drug effects. Signal Transduction / drug effects. Sirolimus / analogs & derivatives. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy


45. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G, Philpott MP, Aberger F: Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol; 2006 Aug;26(16):6283-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hedgehog (HH)/GLI signaling plays a critical role in epidermal development and basal cell carcinoma.
  • Promoter studies of a subset of GLI/EGF-regulated genes, including the genes encoding interleukin-1 antagonist IL1R2, Jagged 2, cyclin D1, S100A7, and S100A9, suggest convergence of EGFR and HH/GLI signaling at the level of promoters of selected direct GLI target genes.
  • We also show that EGF treatment neutralizes GLI-mediated induction of epidermal stem cell marker expression and provide evidence that EGFR signaling is essential for GLI-induced cell cycle progression in epidermal cells.
  • The results suggest that EGFR signaling modulates GLI target gene profiles which may play an important regulatory role in ORS specification, hair growth, and possibly cancer.
  • [MeSH-minor] Binding Sites / genetics. Cell Proliferation. Cells, Cultured. Extracellular Signal-Regulated MAP Kinases / metabolism. Hair Follicle / cytology. Hedgehog Proteins. Humans. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Interleukin-1 / metabolism. Receptors, Interleukin-1 Type II. Stem Cells / cytology. Zinc Finger Protein GLI1


46. Hidayatullah, Obaidullah, Asif M, Tahir M, Aslam M: Aesthetic outcome of sliding island flap for reconstruction of cheek after tumour ablation. J Ayub Med Coll Abbottabad; 2005 Jul-Sep;17(3):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancer is the most common malignancy in humans and the incidence continues to rise.
  • Facial reconstruction after cutaneous tumour ablation is a challenging job and needs thorough knowledge of the anatomy and physiology of face skin, biomechanics of skin and muscles, design of local flaps and their blood supply.
  • METHODS: This study was carried in the department of Plastic and Reconstructive Surgery Postgraduate Medical Institute Hayatabad Medical Complex Peshawar from March 2001 to February 2004.
  • Forty patients with age 50-70 years having Basal Cell Carcinoma on infraorbital and malar area of the cheek were taken for the study.
  • This flap is based on subcutaneous vertical pedicle that vascularizes the skin island through sub dermal plexus.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / surgery. Esthetics. Facial Neoplasms / surgery. Female. Humans. Male. Middle Aged. Skin Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320788.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


47. Schlötzer-Schrehardt U, Stojkovic M, Hofmann-Rummelt C, Cursiefen C, Kruse FE, Holbach LM: The Pathogenesis of floppy eyelid syndrome: involvement of matrix metalloproteinases in elastic fiber degradation. Ophthalmology; 2005 Apr;112(4):694-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate histopathologic alterations of eyelid biopsy specimens from patients with floppy eyelid syndrome (FES) with special regard to elastic fiber content and ultrastructure as well as to the expression of elastin-degrading enzymes to elucidate the pathogenesis of this disorder.
  • DESIGN: Retrospective, interventional case series.
  • PARTICIPANTS AND CONTROLS: Eleven consecutive patients with FES and 10 age-matched control patients with basal cell carcinoma of the eyelid.
  • Histopathologic analysis of the surgical specimens showed, apart from unspecific signs of chronic inflammation, a significant decrease in the amount of elastin within the tarsal plate and eyelid skin as compared with controls.
  • [MeSH-minor] Aged. Biopsy. Carcinoma, Basal Cell. Elastic Tissue / enzymology. Elastic Tissue / ultrastructure. Elastin / metabolism. Eyelid Neoplasms. Female. Humans. Immunoenzyme Techniques. Male. Matrix Metalloproteinase 12. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 7 / metabolism. Matrix Metalloproteinase 9 / metabolism. Metalloendopeptidases / metabolism. Middle Aged. Retrospective Studies. Syndrome

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808264.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-58-3 / Elastin; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.65 / MMP12 protein, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


48. Nassab R, Rayatt S, Peart F: Infected palmar pits: a rare presentation of Gorlin's syndrome. J Hand Surg Br; 2005 Oct;30(5):459-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper presents a rare hand presentation of Gorlin's Syndrome, also known as Naevoid Basal Cell Carcinoma Syndrome, which has not been reported previously.
  • This condition is an autosomal dominant, multisystem condition whose diagnosis is important to ensure further surveillance and treatment of features of the condition not routinely dealt with by hand surgeons.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Cellulitis / etiology. Hand

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055245.001).
  • [ISSN] 0266-7681
  • [Journal-full-title] Journal of hand surgery (Edinburgh, Scotland)
  • [ISO-abbreviation] J Hand Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


49. Elbasmi AA, Fayaz MS, Al-Mohanadi S, Al-Nesf Y, Al-Awadi A: Reliability of the Kuwait Cancer Registry: a comparison between breast cancer data collected by clinical oncologists and registry staff. Asian Pac J Cancer Prev; 2010;11(3):735-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability of the Kuwait Cancer Registry: a comparison between breast cancer data collected by clinical oncologists and registry staff.
  • AIM: The quality of cancer registration is of great importance and the present study was conducted to assess the reliability of Kuwait Cancer Registry data on breast cancer.
  • METHODS: Data from the clinical records extracted by a group of clinical oncologists for another study on 1,235 breast cancer cases diagnosed between 1999 and 2004 were used to audit the data held on these individuals by the Kuwait Cancer Registry (KCR).
  • Only 902 cases met the eligibility criteria.
  • Main measures were sex, nationality, laterality, morphology, stage of disease at time of admission to the center, type of treatment and status at last follow up (alive or dead).
  • CONCLUSIONS: The accuracy of the KCR data seems to be comparable to that found in reviews of other cancer registries.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy. Carcinoma, Medullary / therapy. Physicians. Registries / standards


50. Alshatwi AA: Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms. Food Chem Toxicol; 2010 Jul;48(7):1881-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms.
  • Diet plays an important role in DNA methylation, synthesis, and repair; intake has been associated with breast cancer.
  • The folate-metabolizing enzyme, methylenetetrahydrofolate reductase (MTHFR) is polymorphic at nucleotides 677 (C-->T), resulting in allozymes with altered activity and is thus believed to cause interindividual differences in cancer risk susceptibility.
  • I evaluated this polymorphism and its effect on the food intake and breast cancer risk association in a population-based case-control study of 100 breast cancer cases and 100 controls using a real-time PCR based assay.
  • Cases and controls were similar in the distribution ofMTHFRpolymorphisms at codon 677 (41.4% cases and 41.8% controls carried theTallele).
  • An inverse association of breast cancer risk with food intake was observed in all genotype groups, particularly among subjects with the677TTgenotype.
  • Results of this study suggest that theMTHFR C677T polymorphism may modify the association between dietary intake and breast cancer risk.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Diet. Methylenetetrahydrofolate Reductase (NADPH2) / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20417243.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vitamins; 9007-49-2 / DNA; 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


51. Summers C, Saltzstein SL, Blair SL, Tsukamoto TT, Sadler GR: Racial/ethnic differences in early detection of breast cancer: a study of 250,985 cases from the California Cancer Registry. J Womens Health (Larchmt); 2010 Feb;19(2):203-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/ethnic differences in early detection of breast cancer: a study of 250,985 cases from the California Cancer Registry.
  • AIMS: This study analyzed early breast cancer detection rates as a surrogate for breast cancer mortality rates.
  • Stage at diagnosis was broken down by race/ethnicity and year of diagnosis for the cases of female breast cancer in the California Cancer Registry from 1988 to 2002.
  • METHODS: A quarter million cases of breast cancer in women > or =50 years of age recorded in the California Cancer Registry over the period 1988-2002 were classified as early (in situ and localized stages) or late (regional and distant stages).
  • The increases in the percent of cases that were early were studied by 3-year periods over this interval.
  • The 3-year periods were used to compensate for small numbers of cases in some of the nonwhite groups.
  • RESULTS: The proportion of early stage female breast cancers reached a plateau at 70% in the mid-1990s.
  • Only Pacific Islander/Asian American women demonstrated a sustained rise in the percent of early breast cancers detected through 2002, eventually nearing the rate of early detection set by white women.
  • CONCLUSIONS: The plateaus observed suggest that focused interventions continue to be needed for all women, especially for African American and Hispanic women if the American Cancer Society's 2015 goals are to be achieved.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(3):263-70 [9386870.001]
  • [Cites] Prev Med. 1998 Nov-Dec;27(6):821-9 [9922064.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1903-8 [10371567.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):449-62 [10430253.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):345-61 [15537577.001]
  • [Cites] Arch Intern Med. 2005 Oct 10;165(18):2083-8 [16216997.001]
  • [Cites] Soc Sci Med. 2006 Jan;62(2):337-47 [16051406.001]
  • [Cites] Ann Epidemiol. 2006 Mar;16(3):180-90 [16242959.001]
  • [Cites] J Cancer Educ. 2008;23(3):137 [18709581.001]
  • [Cites] Cancer. 2000 Mar 1;88(5 Suppl):1256-64 [10705364.001]
  • [Cites] J Cancer Educ. 2000 Fall;15(3):168-72 [11019766.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):118-21 [11189802.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):122-5 [11189803.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1299-304 [11571746.001]
  • [Cites] J Community Health. 2002 Feb;27(1):33-51 [11845940.001]
  • [Cites] Am J Public Health. 2002 Apr;92(4):646-54 [11919066.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):909-19 [11918907.001]
  • [Cites] Am J Public Health. 2002 Jul;92(7):1144-50 [12084699.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60 [12204020.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] Breast J. 2003 May-Jun;9 Suppl 2:S101-3 [12713506.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):416-22 [12845683.001]
  • [Cites] Breast J. 2003 Sep-Oct;9(5):347-9 [12968953.001]
  • [Cites] J Behav Med. 1989 Dec;12(6):605-11 [2634113.001]
  • (PMID = 20109117.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P60 MD000220; United States / NCI NIH HHS / CA / 1U54CA132379; United States / NCI NIH HHS / CA / R25 CA65745; United States / NCI NIH HHS / CA / 1U54CA132384; United States / NCI NIH HHS / CA / P30 CA023100
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2834439
  •  go-up   go-down


52. Reincke S, Govbakh L, Wilhelm B, Jin H, Bogdanova N, Bremer M, Karstens JH, Dörk T: Mutation analysis of the MDM4 gene in German breast cancer patients. BMC Cancer; 2008;8:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the MDM4 gene in German breast cancer patients.
  • It is unknown, however, whether MDM4 gene alterations play some role in the inherited component of breast cancer susceptibility.
  • METHODS: We sequenced the whole MDM4 coding region and flanking untranslated regions in genomic DNA samples obtained from 40 German patients with familial breast cancer.
  • Selected variants were subsequently screened by RFLP-based assays in an extended set of breast cancer cases and controls.
  • No association of this allele with breast cancer was found in a subsequent screening of 133 patients with bilateral breast cancer and 136 controls.
  • The D153G substitution only partially segregated with breast cancer in the family and was not identified on additional 680 chromosomes screened.
  • We conclude that there is no evidence for a major role of MDM4 coding variants in the inherited susceptibility towards breast cancer in German patients.
  • [MeSH-major] Breast Neoplasms / genetics. Nuclear Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Base Sequence. Case-Control Studies. DNA Mutational Analysis. Family. Female. Genetic Testing. Germany. Humans. Middle Aged. Molecular Sequence Data. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2006 Mar;27(3):242-8 [16419081.001]
  • [Cites] Nat Rev Genet. 2006 Feb;7(2):98-108 [16418745.001]
  • [Cites] BMC Genomics. 2006;7:67 [16584540.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):927-34 [16543935.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):941-50 [16601750.001]
  • [Cites] J Med Genet. 2006 Jun;43(6):531-3 [16258005.001]
  • [Cites] BMC Cancer. 2006;6:80 [16563154.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):911-9 [16818855.001]
  • [Cites] Hum Mol Genet. 2006 Aug 15;15(16):2490-508 [16825284.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6819-31 [16943424.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1382-96 [17018785.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):909-23 [17128209.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):371-8 [17251377.001]
  • [Cites] Science. 2007 Jan 26;315(5811):466-7 [17185559.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):270-5 [17301259.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6283-91 [17209043.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):352-8 [17293864.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):e26 [17602067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12365-70 [17640893.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):164-71 [12648672.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):2002-5 [15138485.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5835-43 [15199139.001]
  • [Cites] J Comput Biol. 2004;11(2-3):377-94 [15285897.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Nucleic Acids Res. 1997 Jan 1;25(1):217-21 [9016539.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):402-6 [10053113.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8299-308 [10075736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6 [11248061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60 [11535547.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7608-15 [11606401.001]
  • [Cites] Genome Res. 2002 Mar;12(3):436-46 [11875032.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):226-30 [12062170.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] FASEB J. 2003 Mar;17(3):349-68 [12631575.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1144-8 [15756275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 [15788536.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):263-6 [15810020.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5481-4 [15994915.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6509-20 [16024788.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3411-22 [16163388.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9608-20 [16227609.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9687-94 [16266988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31 [16492743.001]
  • (PMID = 18279506.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MDM4 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ PMC2259322
  •  go-up   go-down


53. Lee Ch K, Schwartz J R, Iglesis G R, Vélez F R, Gómez S L: [Occult breast cancer: Report of two cases]. Rev Med Chil; 2006 Sep;134(9):1166-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occult breast cancer: Report of two cases].
  • [Transliterated title] Cancer de mama oculto: dos casos clínicos analizados según el concepto actual.
  • Occult breast cancer is expressed as a metastatic axillary lymph node without clinical or imaging evidence of a primary tumor in the breast.
  • Its incidence is low, representing only 0.3 to 1% of all breast cancer cases.
  • The treatment of isolated axillary metastases of breast cancer is controversial.
  • However, in patients without radiological lesions in the breast, the tendency is not to perform a radical mastectomy as previously recommended, since the primary tumor will not be found in the surgical specimen in two thirds of cases.
  • We report two patients with a well defined occult breast cancer and based on them, a review of the subject is attempted.
  • Considering its prognosis, physicians should be aware of this uncommon and difficult to diagnose disease.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Aged. Axilla. Biopsy. Breast / pathology. Combined Modality Therapy / methods. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Mammography. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171219.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


54. Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TI: Growth patterns and the risk of breast cancer in women. Int J Gynecol Cancer; 2006;16 Suppl 2:569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth patterns and the risk of breast cancer in women.
  • Adult height and body mass index (BMI) influence the risk of breast cancer in women.
  • We investigated the association between growth during childhood and the risk of breast cancer in a cohort of 117,415 Danish women.
  • Information on vital status, age at first childbirth, parity, and diagnosis of breast cancer was obtained through linkages to national registries.
  • During 3,333,359 person-years of follow-up, 3340 cases of breast cancer were diagnosed.
  • High birth weight, high stature at 14 years of age, low BMI at 14 years of age, and peak growth at an early age were independent risk factors for breast cancer.
  • Height at 8 years of age and the increase in height during puberty (8-14 years of age) were also associated with breast cancer.
  • Birth weight and growth during childhood and adolescence influence the risk of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17010075.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. González-Pérez A, García Rodríguez LA: Breast cancer risk among users of antidepressant medications. Epidemiology; 2005 Jan;16(1):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer risk among users of antidepressant medications.
  • BACKGROUND: Breast cancer is the most common cancer in women.
  • Laboratory studies suggest that antidepressants may promote breast cancer tumor growth.
  • METHODS: We conducted a cohort study with a secondary nested case-control analysis based on the General Practice Research Database.
  • Our goal was to assess the association between the risk of breast cancer and use of serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and other antidepressants.
  • We calculated adjusted estimates controlling for breast cancer risk factors using unconditional logistic regression.
  • RESULTS: A total of 3708 cases of breast cancer were ascertained.
  • Overall, antidepressant use was not associated with an increased risk of breast cancer.
  • None of the individual drugs was associated with breast cancer risk.
  • CONCLUSIONS: Use of antidepressants was not associated with an increased risk of breast cancer regardless of duration of use, daily dose, or specific drug being used.
  • These results, together with evidence from prior studies, support the lack of a clinically meaningful association between breast cancer risk and antidepressants.
  • [MeSH-major] Antidepressive Agents / adverse effects. Breast Neoplasms / chemically induced
  • [MeSH-minor] Case-Control Studies. Cohort Studies. Humans. Logistic Models. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613952.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


56. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J: Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet; 2005 Oct 29-Nov 4;366(9496):1554-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
  • BACKGROUND: The allele CHEK2*1100delC doubles the risk of breast cancer in unselected women, but could confer a greater risk in women with a family history of the disease, particularly of bilateral breast cancer.
  • Our aim was to measure the risk of breast cancer in relatives of women with bilateral breast cancer who were carriers of this allele.
  • METHODS: A population-based series of 469 bilateral breast cancer cases ascertained through English cancer registries were genotyped for CHEK2*1100delC.
  • Standardised incidence ratios (SIRs) and cumulative risks were calculated for breast cancer, prostate cancer, and all other cancers in the first-degree relatives of carriers and non-carriers.
  • FINDINGS: The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36).
  • Relatives of those who were carriers of CHEK2*1100delC had a substantially higher risk of breast cancer (eight cases: SIR 12.11, 5.23-23.88) and possibly prostate cancer (two cases: SIR 9.87, 1.20-35.67).
  • In women with a family history of bilateral disease, CHEK2*1100delC confers a high lifetime risk and might be useful for predictive testing.
  • Bilateral breast cancer cases and their families are likely to provide an efficient basis for identification of additional low-penetrance breast-cancer genes.
  • [MeSH-major] Breast Neoplasms / genetics. DNA, Neoplasm / isolation & purification. Prostatic Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics


57. Nouri K, Ballard CJ, Bouzari N, Saghari S: Basal cell carcinoma of the areola in a man. J Drugs Dermatol; 2005 May-Jun;4(3):352-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the areola in a man.
  • Basal cell carcinomas (BCCs) that arise in sun-protected sites are quite uncommon.
  • We report a case of BCC of the areola, which is extremely rare.
  • The etiologic factors of BCCs in sun-protected areas are discussed, and previous studies regarding the treatment modalities are reviewed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nipples / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898292.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Sloane PD, Brooker D, Cohen L, Douglass C, Edelman P, Fulton BR, Jarrott S, Kasayka R, Kuhn D, Preisser JS, Williams CS, Zimmerman S: Dementia care mapping as a research tool. Int J Geriatr Psychiatry; 2007 Jun;22(6):580-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DCM coding involves continuous observation over a 6-h period, with observers recording a Behavior Category Code (BCC, a recording of activity/interaction) and a Well/Ill Being (WIB) score at 5 min intervals.
  • RESULTS: Issues and problems identified include: complex scoring algorithms, inter-rater reliability of the BCCs, limited variability of WIB values, associations between resident characteristics and DCM assessments, rater time burden, and comparability of results across study settings.
  • [MeSH-major] Activities of Daily Living / psychology. Alzheimer Disease / therapy. Health Services Research. Long-Term Care / psychology. Quality Assurance, Health Care. Quality of Life / psychology. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 17173340.001).
  • [ISSN] 0885-6230
  • [Journal-full-title] International journal of geriatric psychiatry
  • [ISO-abbreviation] Int J Geriatr Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


59. Miñán A, Bosch A, Lasch P, Stämmler M, Serra DO, Degrossi J, Gatti B, Vay C, D'aquino M, Yantorno O, Naumann D: Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry. Analyst; 2009 Jun;134(6):1138-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry.
  • Two approaches based on intact cell matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (IC-MALDI-ToF MS) have been evaluated in order to discriminate and identify nine former Burkholderia cepacia complex (Bcc) species, Burkholderia contaminans belonging to the novel Taxon K, Burkholderia gladioli, and the most relevant non-fermentative (NF) Gram-negative rods recovered from cystic fibrosis (CF) sputum cultures.
  • In a first approach, spectral analysis was carried out by means of a gel-view representation of mass spectra, which turned out to be useful to recognize specific identifying biomarker proteins (SIBPs).
  • Both complementary modalities of analyzing complex IC-MALDI-ToF MS data open the path towards a rapid, accurate and objective means of routine clinical microbiology diagnosis of pathogens from sputum samples of CF patients.
  • [MeSH-major] Burkholderia cepacia / isolation & purification. Cystic Fibrosis / microbiology. Cystic Fibrosis / pathology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization


60. Boneberger S, Ruzicka T, Rupec RA: [Diagnostic pitfall: basal cell carcinoma arising in a therapy-resistant chronic venous ulcer of the lower leg]. Dtsch Med Wochenschr; 2009 Feb;134(6):243-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic pitfall: basal cell carcinoma arising in a therapy-resistant chronic venous ulcer of the lower leg].
  • [Transliterated title] Diagnostische Falle: ein Basalzellkarzinom unter dem Bild eines therapieresistenten Ulcus cruris.
  • HISTORY: A 96-year-old woman attended our department with an ulcer on the lower leg.
  • It looked typical of an ulcer due to chronic venous insufficiency an had been resistant to treatment for 20 years.
  • INVESTIGATIONS: On the left lower leg there was a 5 x 5 cm ulcer with a sharply demarkated border.
  • DIAGNOSIS, TREATMENT AND CLINICAL COURSE: Histopathologically examination revealed a basal cell carcinoma.
  • The ulcer was excised with a wide margin and the wound closed with a mesh-graft.
  • CONCLUSION: This case demonstrates the need of re-evaluating the pathology of chronic ulcers due to venous stasis in the leg to exclude malignancy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Leg Ulcer / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Female. Humans. Treatment Outcome. Venous Insufficiency / complications

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180415.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Green WH, Wang SQ, Cognetta AB Jr: Total-body cutaneous examination, total-body photography, and dermoscopy in the care of a patient with xeroderma pigmentosum and multiple melanomas. Arch Dermatol; 2009 Aug;145(8):910-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total-body cutaneous examination, total-body photography, and dermoscopy in the care of a patient with xeroderma pigmentosum and multiple melanomas.
  • BACKGROUND: Xeroderma pigmentosum (XP) is an autosomal recessive disorder characterized by a defect in DNA repair and subsequent increased frequency of cutaneous malignant neoplasms, including melanoma.
  • In patients with XP, patient and family education and aggressive UV radiation protection are the primary means of skin cancer prevention.
  • An important secondary measure in decreasing morbidity and mortality in these patients involves early detection of skin cancers, particularly melanomas.
  • OBSERVATIONS: We describe a 39-year-old woman with XP who developed 38 primary melanomas along with 6 squamous cell carcinomas and 70 basal cell carcinomas over a 23-year period.
  • The ratio of benign to malignant biopsied suspicious melanocytic lesions during 23 years of follow-up was 0.9:1.
  • All melanomas were treated using wide local excision, and she had no evidence of local or in-transit metastases of any of her malignant neoplasms at the most recent follow-up examination.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Photography. Physical Examination. Skin Neoplasms / diagnosis. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Humans


62. Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A: Development of malignancy following living donor kidney transplantation. Transplant Proc; 2005 Sep;37(7):3065-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the follow-up, 38 patients (1.8%) developed cancer: 14 Kaposi's sarcomas, 11 lymphoproliferative diseases, four squamous cell carcinomas of the skin, two basal cell carcinomas, one breast, one ovary, one melanoma, one seminoma, one lung, and one ovary.
  • Mean age at transplantation in the malignancy cases was higher than the other recipients (43.5 +/- 12.1 vs 32 +/- 13.9 years) (P = .000).
  • We also observed that patients treated with mycophenolate mofetil developed cancer earlier than the others (19 vs 52 months; P = .001).
  • None of the cases with lymphoma had a history of antilymphocytic agent therapy.
  • CONCLUSION: The prevalence of cancer (1.8%) was among the lowest compared with other studies possibly due to implementing a living donor kidney transplantation program that required a low frequency of induction therapy.


63. Skelton LA: The effective treatment of basal cell carcinoma. Br J Nurs; 2009 Mar 26-Apr 8;18(6):346, 348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effective treatment of basal cell carcinoma.
  • Basal cell carcinoma (BCC) accounts for 75% of all skin cancers and its incidence is rising by between 3-8% each year (Szeimies and Karrer, 2006).
  • As a result, the development of new therapeutic strategies and treatment methods for the removal of BCC is crucial in combating what is a growing problem.
  • The aim of this article is to critically review some of the current literature in order to substantiate the efficacy of destructive and non-surgical techniques as reliable alternatives to surgery for the management/removal of BCCs.
  • However, in relation to success rates, patients tolerance of the treatment and cosmetic outcomes, and depending on the type of BCC involved, other treatment methods do offer reliable alternatives.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Administration, Cutaneous. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Causality. Cryosurgery. Curettage. Great Britain / epidemiology. Humans. Incidence. Interferon-alpha / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local / prevention & control. Nurse's Role. Oncology Nursing. Photochemotherapy. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329898.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99011-02-6 / imiquimod
  • [Number-of-references] 26
  •  go-up   go-down


64. Bikle DD: Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J Invest Dermatol; 2008 Oct;128(10):2357-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism.
  • More than 1 million skin cancers occur annually in the United States--of which 80% are basal-cell carcinoma (BCC), 16% are squamous-cell carcinoma (SCC), and 4% are melanomas--making skin cancer by far the most common cancer (Greenlee et al., 2001).
  • Thus, UVB, with a spectrum between 280 and 320 nm, is the major cause of these cancers (Freeman et al., 1989), but this is the same spectrum required for vitamin D production in the skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Invest Dermatol. 2008 Oct;128(10):2508-17 [18509362.001]
  • (PMID = 18787544.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR038386; United States / NIAMS NIH HHS / AR / R01 AR050023; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NIAMS NIH HHS / AR / R01 AR0550023
  • [Publication-type] Comment; Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Tumor Suppressor Proteins; 1406-16-2 / Vitamin D
  •  go-up   go-down


65. dos Santos VM, Cintra Osterne EM, de Castro RA, Marques HV Jr: Bilateral male breast cancer: too many concerns? Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):640-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral male breast cancer: too many concerns?
  • The male breast cancer accounts for nearly 1% of all breast cancer cases and bilateral involvement occurs in less than 2% of the cases.
  • Estrogen treatment for prostate cancer is a risk factor for primary breast cancer.
  • Bilateral breast carcinomas were found in a 79-year-old Brazilian black man, following prostate cancer treatment with estrogen.
  • Prostate cancer metastases could be found in breast tissue, and might be indistinguishable from primary breast tumours on histological evaluation without immunohistochemistry.
  • Coexistence of prostate cancer with breast cancer increases future-longevity concerns.
  • [MeSH-major] Breast Neoplasms, Male / chemically induced. Estrogens / adverse effects. Prostatic Neoplasms / drug therapy


66. Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A: Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc; 2007 Dec;39(10):3093-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One basal cell carcinoma of skin was detected.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089329.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Recombinant Fusion Proteins; 0 / basiliximab; 83HN0GTJ6D / Cyclosporine; CUJ2MVI71Y / daclizumab
  •  go-up   go-down


67. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, Lowe NJ, Jarratt MT, Murrell DF, Rich P, Pariser DM, Oseroff AR, Barnetson R, Anderson C, Kossard S, Gibson LE, Tope WD: Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol; 2009 Nov;48(11):1236-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
  • BACKGROUND: Data suggest that photodynamic therapy using topical methyl aminolevulinate (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell carcinoma (BCC).
  • In the studies described here, we investigated the histologic response, tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (<or= 5 mm in depth).
  • Lesions with a partial response (>or= 50% reduction in greatest diameter) at 3 months were re-treated (21%).
  • CONCLUSION: Although longer follow-up studies are required, these promising data indicate the potential of topical MAL PDT as a noninvasive treatment alternative for nodular BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064185.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


68. Younis LK, El Sakka H, Haque I: The Prognostic Value of E-cadherin Expression in Breast Cancer. Int J Health Sci (Qassim); 2007 Jan;1(1):43-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Prognostic Value of E-cadherin Expression in Breast Cancer.
  • BACKGROUND: Breast cancer continues to be a major cause of morbidity and mortality throughout the world.
  • The behavior of breast cancer varies widely.
  • Several parameters have been investigated to predict the prognosis in breast cancer.
  • Among the novel prognostic markers is E-cadherin; a calcium-dependent epithelial cell adhesion molecule.
  • The objective of the present study was to assess the prognostic value of E-cadherin expression in breast cancer cases, and its correlations with the other studied prognostic parameters.
  • METHODS: The study comprised 54 breast cancer patients admitted at King Fahd Specialist Hospital, Qassim during the period 2001-2006.
  • Fifty cases (92.6%) had invasive ductal carcinoma, four cases had lobular carcinomas, and most were grade II (82%), stage II (48%), and the majority of cases had positive axillary lymph nodes (70.3%).
  • Representative sections from formalin-fixed paraffin embedded tissue blocks were taken from the 54 cases of breast cancer, and were stained for E-cadherin expression by immunohistochemical technique (monoclonal E-cadherin (NCL-E-cad), Novocastra).
  • All the lobular carcinoma cases were negative for membranous expression of E-cadherin while 72% of invasive ductal carcinomas were positive for the marker.
  • RESULTS: A significant correlation was found between strong E-cadherin expression and node negative cases.
  • Node negative cases were found to be an independent predictor of strong E-cadherin expression while node positive cases predicted negative expression of E-cadherin (P = 0 .026).
  • Also loss of E-cadherin was noted in advanced stages of breast cancer supporting the view that loss of E-cadherin expression is a marker of aggressiveness.
  • CONCLUSION: A significant correlation was found between strong E-cadherin expression and node negative cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1067-75 [14614045.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):151-71 [11476987.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Saudi Med J. 2001 Feb;22(2):110-3 [11299401.001]
  • [Cites] Saudi Med J. 2000 Sep;21(9):869-72 [11376366.001]
  • [Cites] J Pak Med Assoc. 2001 Jul;51(7):243-7 [11558215.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1958-63 [11747340.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):10-26 [11753038.001]
  • [Cites] Saudi Med J. 2002 Oct;23(10):1210-3 [12436125.001]
  • [Cites] Saudi Med J. 2003 Jun;24(6):623-7 [12847591.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Indian J Med Sci. 1991 Apr;45(4):85-7 [1660447.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):48-51 [1500227.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):561-7 [9066580.001]
  • (PMID = 21475451.001).
  • [ISSN] 1658-3639
  • [Journal-full-title] International journal of health sciences
  • [ISO-abbreviation] Int J Health Sci (Qassim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3068666
  • [Keywords] NOTNLM ; E-cadherin / breast cancer / immunohistochemistry / immunostaining / prognostic factors
  •  go-up   go-down


69. Dai Y, Li JH, Liu BX: Long-range empirical potential model: extension to hexagonal close-packed metals. J Phys Condens Matter; 2009 Sep 23;21(38):385402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An n-body potential is developed and satisfactorily applied to hcp metals, Co, Hf, Mg, Re, Ti, and Zr, in the form of long-range empirical potential.
  • The potential can well reproduce the lattice constants, c/a ratios, cohesive energies, and the bulk modulus for their stable structures (hcp) and metastable structures (bcc or fcc).
  • The proposed potential is shown to be relevant for describing the interaction of bcc, fcc and hcp metal systems, bringing great convenience for researchers in constructing potentials for metal systems constituted by any combination of bcc, fcc and hcp metals.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21832367.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Duggan MA, Khalil M, Brasher PM, Nation JG: Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. Cytopathology; 2006 Apr;17(2):73-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of normal [within normal limits (WNL) and benign cellular changes (BCC)] results in the ThinPrep cohort was 6% lower and the frequency of abnormal [> or =atypical squamous cells of undetermined significance (ASCUS)] results was 6.8% higher.
  • Respective ThinPrep and conventional cohort results were 1156 (51%) and 1291 (58%) WNL, 625 (27%) and 561 (25%) BCC, 101 (4%) and 65 (3%) ASCUS, 21 (1%) and 2 (0.1%) atypical glandular cells of undetermined significance, 301 (13%) and 224 (10%) low-grade squamous intraepithelial lesion (LSIL), and 74 (3%) and 40 (2%) high-grade SIL (HSIL) (P < 0.0001).
  • [MeSH-major] Cytodiagnosis / methods. Uterine Cervical Diseases / diagnosis. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548991.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


71. Baldwin A, Mahenthiralingam E, Thickett KM, Honeybourne D, Maiden MC, Govan JR, Speert DP, Lipuma JJ, Vandamme P, Dowson CG: Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J Clin Microbiol; 2005 Sep;43(9):4665-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.
  • A single multilocus sequence typing (MLST) scheme was developed for precise characterization of the opportunistic pathogens of Burkholderia cepacia complex (BCC), a group composed of at least nine closely related species.
  • MLST differentiated all nine current BCC species and identified 114 sequence types within a collection of 119 strains.
  • The improved resolution in strain identification offered by MLST was able to identify previously characterized epidemic strain lineages and also demonstrated the presence of four novel potential species groups within the complex.
  • There was also evidence for recombination having an important role in the recent evolution of individual BCC species.
  • This highly transferable, validated, MLST scheme provides a new means to assist in species identification as well as unambiguous strain discrimination of the BCC by a single approach.
  • It is also the first MLST scheme designed at the outset to incorporate multiple species and should facilitate global epidemiological investigations of the BCC.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Syst Bacteriol. 1997 Oct;47(4):1188-200 [9336927.001]
  • [Cites] J Clin Microbiol. 1996 Dec;34(12):2914-20 [8940422.001]
  • [Cites] Clin Chest Med. 1998 Sep;19(3):473-86, vi [9759550.001]
  • [Cites] Microbiology. 1998 Nov;144 ( Pt 11):3049-60 [9846740.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1197-205 [10191223.001]
  • [Cites] J Clin Microbiol. 2004 Dec;42(12):5644-9 [15583294.001]
  • [Cites] Infect Immun. 2000 Jan;68(1):24-9 [10603364.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):910-3 [10655415.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1042-7 [10698993.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1206-12 [10764313.001]
  • [Cites] Chest. 2000 Jun;117(6):1661-5 [10858399.001]
  • [Cites] J Clin Microbiol. 2000 Sep;38(9):3165-73 [10970351.001]
  • [Cites] J Clin Microbiol. 2001 Mar;39(3):990-4 [11230416.001]
  • [Cites] Cell Microbiol. 2001 Jun;3(6):381-93 [11422081.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6 [11435245.001]
  • [Cites] J Clin Microbiol. 2001 Aug;39(8):2891-6 [11474009.001]
  • [Cites] Int J Syst Evol Microbiol. 2001 Jul;51(Pt 4):1481-90 [11491349.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3427-36 [11574551.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1230-1 [11751234.001]
  • [Cites] J Med Microbiol. 2002 Jul;51(7):533-8 [12132768.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3300-7 [12202570.001]
  • [Cites] J Med Microbiol. 2002 Nov;51(11):937-40 [12448677.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1623-36 [12682154.001]
  • [Cites] J Clin Microbiol. 2003 May;41(5):2068-79 [12734250.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2797-8 [12791937.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4113-20 [12958234.001]
  • [Cites] Appl Environ Microbiol. 2003 Dec;69(12):7257-65 [14660374.001]
  • [Cites] Clin Microbiol Rev. 2004 Jan;17(1):57-71 [14726455.001]
  • [Cites] Science. 2004 Apr 2;304(5667):66-74 [15001713.001]
  • [Cites] Int J Syst Evol Microbiol. 2004 May;54(Pt 3):689-91 [15143009.001]
  • [Cites] J Mol Biol. 2004 Jun 25;340(1):49-65 [15184022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14246-51 [15377793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14240-5 [15377794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4384-8 [8506277.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1007-17 [8629607.001]
  • [Cites] FEMS Microbiol Lett. 1996 Nov 1;144(2-3):117-28 [8900054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5 [9501229.001]
  • (PMID = 16145124.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Bacterial
  • [Other-IDs] NLM/ PMC1234123
  •  go-up   go-down


72. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol; 2007 Nov 1;25(31):4952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
  • PURPOSE: With mammographic screening, the frequency of diagnosis of stage T1a,bN0M0 breast cancer has increased.
  • We reviewed T1a,bN0M0 breast cancer cases registered in the Surveillance, Epidemiology, and End Results (SEER) Program to investigate the impact of prognostic factors on breast cancer-specific (BCSM) and non-breast cancer-related mortality.
  • METHODS: We identified T1a,bN0M0 breast cancer cases registered in the SEER Program from 1988 to 2001, and used the Kaplan-Meier product limit method to describe overall survival (OS).
  • We estimated the probabilities of death resulting from breast cancer and from other causes, and analyzed associations of patient and tumor characteristics with OS, BCSM, and non-breast cancer-related mortality using the log-rank test, Cox proportional hazards models, and a competing-risk model.
  • RESULTS: We identified 51,246 T1a,bN0M0 cases.
  • Median age at diagnosis was 65 years (range, 20 to 101 years).
  • Characteristics associated with increased probability of BCSM included age younger than 50 years at diagnosis, high tumor grade, estrogen receptor-negative status, progesterone receptor-negative status, and fewer than six nodes removed at axillary dissection.
  • The constructed nomograms allow a comparison of predicted breast cancer-specific survival and non-breast cancer-specific survival in individual patients.
  • CONCLUSION: Overall, the prognosis of patients with T1a,bN0M0 breast cancer is excellent.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. SEER Program. Survival Analysis. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO: Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res; 2009 Jul 1;15(13):4460-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy.
  • However, other than single-case and anecdotal reports, this phenomenon has not been examined following clinical PDT.
  • To determine whether PDT in a clinical setting enhances systemic recognition of tumor cells, we examined whether PDT of basal cell carcinoma resulted in an increased systemic immune response to Hip1, a tumor antigen associated with basal cell carcinoma.
  • EXPERIMENTAL DESIGN: Basal cell carcinoma lesions were either treated with PDT or surgically removed.
  • RESULTS: Immune recognition of Hip1 increased in patients whose basal cell carcinoma lesions were treated with PDT.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):43-51 [12049813.001]
  • [Cites] J Clin Laser Med Surg. 2002 Feb;20(1):3-7 [11902352.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1772-9 [12771994.001]
  • [Cites] Photochem Photobiol. 2003 Jul;78(1):75-81 [12929752.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:5-8 [14616337.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] J Exp Med. 2004 Mar 15;199(6):753-61 [15024045.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2120-6 [15026352.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2192-201 [15169808.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Urology. 1990 Aug;36(2):167-71 [2117309.001]
  • [Cites] Eur J Immunol. 1991 Sep;21(9):2025-31 [1909640.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):5930-5 [7504010.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] Photochem Photobiol. 1995 Oct;62(4):780-9 [7480155.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2555-8 [9205052.001]
  • [Cites] Neoplasma. 1997;44(3):192-6 [9372862.001]
  • [Cites] Photochem Photobiol. 1998 Mar;67(3):358-62 [9523536.001]
  • [Cites] Curr Opin Genet Dev. 1998 Feb;8(1):88-94 [9529611.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S146-56 [9806617.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):617-21 [10050855.001]
  • [Cites] Int Immunopharmacol. 2006 Aug;6(8):1259-66 [16782538.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):535-45 [16794636.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1287-92 [17107404.001]
  • [Cites] Drugs. 2007;67(6):915-34 [17428108.001]
  • [Cites] J Natl Compr Canc Netw. 2007 May;5(5):531-40 [17509255.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1839-48 [17505510.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):950-2 [17913664.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10501-10 [17974994.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2008;27(1):35-42 [18551894.001]
  • [Cites] Photochem Photobiol Sci. 2002 Jan;1(1):79-80 [12659153.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7844-51 [10630637.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):192-6 [11196160.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):739-42 [11348463.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):712-20 [11723800.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):69-73 [11841368.001]
  • [CommentIn] Clin Cancer Res. 2009 Jul 1;15(13):4252-3 [19509131.001]
  • (PMID = 19549769.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R01 CA098156; United States / NCI NIH HHS / CA / CA055791-16; United States / NCI NIH HHS / CA / P01 CA055791; United States / NCI NIH HHS / CA / P01 CA055791-16
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIP1 protein, human; 0 / HLA-A2 Antigen; 0 / Peptide Fragments
  • [Other-IDs] NLM/ NIHMS166195; NLM/ PMC2805024
  •  go-up   go-down


74. Tuccari G, Giuffrè G, Scarf R, Simone A, Todaro P, Barresi G: Immunolocalization of lactoferrin in surgically resected pigmented skin lesions. Eur J Histochem; 2005 Jan-Mar;49(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalization of lactoferrin in surgically resected pigmented skin lesions.
  • Lactoferrin (Lf) expression was determined immunohistochemically in 57 formalin-fixed paraffin-embedded bioptic samples obtained from an equal number of patients treated by surgery to remove pigmented skin lesions (nevi = 23; melanoma = 12; vulgaris and seborrhoeic warts = 12; basal cell carcinoma = 10); in addition, 10 specimens of normal skin were studied as control.
  • Melanocytic cells, regardless of their benign or malignant nature, were consistently stained, with no significant differences in the Lf ID-score between melanomas or nevi.
  • On the contrary, basal cell carcinomas were always unstained, while a slight Lf positivity was found in focal keratinized areas present in two tumours showing baso-squamous differentiation.
  • The biological meaning of Lf in these cases of human skin specimens remains unexplained, although it cannot be ruled out that Lf might be involved in the defense system against tumours, or alternatively, may be used by cells requiring iron availability for their turnover.
  • Finally, the involvement of Lf in skin squamous non-neoplastic elements could be related to its role as one of the molecules modulating an unspecific inflammatory or anti-oxidant response.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Lactoferrin / analysis. Melanoma / pathology. Nevus / pathology. Skin Neoplasms / pathology. Warts / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Skin Pigmentation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823792.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


75. Kijima Y, Yoshinaka H, Higuchi I, Owaki T, Aikou T: A case of amyotrophic lateral sclerosis and breast cancer. Breast Cancer; 2005;12(1):57-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of amyotrophic lateral sclerosis and breast cancer.
  • We report a case of breast cancer occurring in a patient with amyotrophic lateral sclerosis (ALS).
  • A 58-year-old Japanese woman diagnosed with ALS 6 years previously noticed a mass in the left breast.
  • Invasive ductal carcinoma without lymph node metastasis was diagnosed.
  • The patient has been cancer-free for 11 months since her operation and no improvement has been seen in her neurological condition.
  • To the best of our knowledge, this is the first case of breast cancer occurring in a patient with ALS in Japan.
  • [MeSH-major] Amyotrophic Lateral Sclerosis / complications. Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications


76. Hiraldo A, Gómez-Moyano E, Martínez S, Sanz A: [Melanomas and basal cell carcinomas in a patient with Parkinson disease]. Actas Dermosifiliogr; 2010 Jan-Feb;101(1):95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanomas and basal cell carcinomas in a patient with Parkinson disease].
  • [Transliterated title] Melanomas y carcinomas basocelulares en un paciente con enfermedad de Parkinson.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Melanoma / complications. Neoplasms, Multiple Primary / complications. Parkinson Disease / complications. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Antiparkinson Agents / adverse effects. Antiparkinson Agents / therapeutic use. Disease Susceptibility. Dopamine / biosynthesis. Dopamine Agonists / adverse effects. Dopamine Agonists / therapeutic use. Humans. Levodopa / adverse effects. Levodopa / therapeutic use. Male. Melanins / biosynthesis

  • Genetic Alliance. consumer health - Parkinson Disease.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20109402.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Dopamine Agonists; 0 / Melanins; 46627O600J / Levodopa; VTD58H1Z2X / Dopamine
  •  go-up   go-down


77. Barnes EA, Dickinson AJ, Langtry JA, Lawrence CM: The role of Mohs excision in periocular basal cell carcinoma. Br J Ophthalmol; 2006 May;90(5):660-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Mohs excision in periocular basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery. Neoplasm Recurrence, Local / prevention & control. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1984 Mar;73(3):492-7 [6701225.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] Br J Ophthalmol. 2005 Aug;89(8):992-4 [16024851.001]
  • [Cites] Br J Plast Surg. 1993 Oct;46(7):599-606 [8252270.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [CommentOn] Br J Ophthalmol. 2005 Aug;89(8):992-4 [16024851.001]
  • (PMID = 16622110.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1857024
  •  go-up   go-down


78. Micali G, Lacarrubba F, Dinotta F, Massimino D, Nasca MR: Treating skin cancer with topical cream. Expert Opin Pharmacother; 2010 Jun;11(9):1515-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating skin cancer with topical cream.
  • IMPORTANCE OF THE FIELD: Topical pharmacotherapy is an approach to consider in selected skin cancers.
  • This paper reviews and discusses the use of topical pharmacotherapy in the treatment of skin cancer.
  • AREAS COVERED IN THIS REVIEW: This paper examines the existing literature and updates current knowledge of topical pharmacotherapy for skin cancer using fluorouracil, imiquimod, diclofenac and retinoids.
  • WHAT THE READER WILL GAIN: There is a gap between current and best practice in that the use of pharmacotherapy in the treatment of skin cancer is only partially known.
  • TAKE HOME MESSAGE: Topical pharmacotherapy represents an option for treatment of actinic keratoses and selected basal cell carcinomas.
  • Moreover, preliminary reports indicate imiquimod to be effective for skin or mucosal cancers such as Bowen's disease, erythroplasia of Queyrat and lentigo maligna.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408746.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Retinoids; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


79. Sramek B, Lisle A, Loy T: Immunohistochemistry in ocular carcinomas. J Cutan Pathol; 2008 Jul;35(7):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry in ocular carcinomas.
  • BACKGROUND: The distinction between ocular sebaceous carcinoma, poorly differentiated ocular squamous cell carcinoma and ocular basal cell carcinoma can be challenging.
  • RESULTS: Positive staining for cytokeratin (CK)7 was seen in 100% of sebaceous carcinomas, 77.8% of basal cell carcinomas and 67.7% of squamous cell carcinomas.
  • One hundred percent of sebaceous and basal cell carcinomas were positive for cytokeratin CAM 5.2, while only 83.3% of squamous cell carcinomas were positive.
  • Using epithelial membrane antigen (EMA), 100% of squamous cell carcinomas and 80% of sebaceous carcinomas were positive, while basal cell carcinomas were uniformly negative.
  • One hundred percent of basal cell carcinomas and 80% of sebaceous carcinomas were positive for Ber-EP4, while all squamous cell carcinomas were negative.
  • Finally, 77.8%, 20% and 16.7% of basal cell carcinomas, sebaceous carcinomas and squamous cell carcinomas showed immunoreactivity for the androgen receptor.
  • CONCLUSION: An EMA positive, Ber-EP4 positive immunophenotype supports sebaceous carcinoma, EMA positive, Ber-EP4 negative result supports squamous cell carcinoma and an EMA negative, Ber-EP4 positive result supports basal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Eye Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology. Skin / pathology
  • [MeSH-minor] Biomarkers / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7 / metabolism. Keratins / metabolism. Mucin-1 / metabolism. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201230.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Keratin-7; 0 / Mucin-1; 0 / Receptors, Androgen; 0 / human epithelial antigen-125; 68238-35-7 / Keratins
  •  go-up   go-down


80. Moustafa T, Girod S, Tortosa F, Li R, Sol JC, Rodriguez F, Bastide R, Lazorthes Y, Sallerin B: Viability and functionality of bovine chromaffin cells encapsulated into alginate-PLL microcapsules with a liquefied inner core. Cell Transplant; 2006;15(2):121-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Implantation of adrenal medullary bovine chromaffin cells (BCC), which synthesize and secrete a combination of pain-reducing neuroactive compounds including catecholamines and opioid peptides, has been proposed for the treatment of intractable cancer pain.
  • In the present study, we report the viability and functionality of BCC encapsulated into microcapsules of alginate-poly-L-lysine (PLL) with a liquefied inner core.
  • At the same time, the viability and functionality of both encapsulated and nonencapsulated BCC were evaluated in vitro.
  • We obtained viable BCC with excellent functionality: immunocytochemical analysis revealed robust survival of chromaffin cells 30 days after isolation and microencapsulation.
  • HPLC assay showed that encapsulated BCC released catecholamines basally during the time course study.
  • Taken together, these results demonstrate that viable BCC can be successfully encapsulated into alginate-PLL microcapsules with a liquefied inner core.
  • [MeSH-major] Alginates. Biocompatible Materials. Cell Transplantation / methods. Chromaffin Cells / transplantation. Polylysine / analogs & derivatives
  • [MeSH-minor] Animals. Blotting, Western. Capsules. Catecholamines / metabolism. Cattle. Cell Survival / physiology. Cells, Cultured. Chromatography, High Pressure Liquid. Immunohistochemistry. Implants, Experimental. Microscopy, Confocal. Microscopy, Electron, Scanning. Neoplasms / complications. Pain Management. Permeability. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719046.001).
  • [ISSN] 0963-6897
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alginates; 0 / Biocompatible Materials; 0 / Capsules; 0 / Catecholamines; 0 / alginate-polylysine-alginate; 25104-18-1 / Polylysine
  •  go-up   go-down


81. Pietarinen-Runtti P, Apajalahti S, Robinson S, Passador-Santos F, Leivo I, Mäkitie AA: Cystic neck lesions: clinical, radiological and differential diagnostic considerations. Acta Otolaryngol; 2010 Feb;130(2):300-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Metastatic disease should always be considered as a potential differential diagnosis in the adult patient with a cystic neck lesion.
  • OBJECTIVES: The most common cause of a cystic neck lesion in young adults is a branchial cleft cyst (BCC).
  • In older patients metastatic lymph nodes may be easily misdiagnosed as BCC.
  • This study aimed to investigate the incidence of unsuspected carcinoma in routinely excised cervical cysts at a tertiary care teaching hospital and to determine the characteristics of benign BCC and cystic malignancy in preoperative imaging.
  • PATIENTS AND METHODS: A total of 196 consecutive adult patients operated on with the initial diagnosis of benign lateral cervical cyst were identified and the hospital charts and imaging studies were reviewed.
  • RESULTS: Metastatic squamous cell carcinoma was demonstrated histologically postoperatively in six (3.1%) patients and metastatic papillary thyroid carcinoma in one (0.5%) patient.
  • Therefore, the incidence of unsuspected carcinoma in the cystic neck lesions initially diagnosed as BCC was 3.6%.
  • The preoperative imaging appearances of these lesions had been considered identical to that of BCC.
  • [MeSH-major] Branchioma / pathology. Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / secondary. Lymphatic Metastasis / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Incidence. Male. Middle Aged. Neck. Neoplasm Staging. Prevalence. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593684.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Jones SE, McMahon KD: Species-sorting may explain an apparent minimal effect of immigration on freshwater bacterial community dynamics. Environ Microbiol; 2009 Apr;11(4):905-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Species-sorting may explain an apparent minimal effect of immigration on freshwater bacterial community dynamics.
  • Long distance atmospheric transport of bacterial cells is often implied as a driver of the apparent cosmopolitan distribution of bacterial taxa.
  • Surprisingly, efforts to measure immigration in bacterial communities are rare.
  • An 8-week time series of within-lake bacterial community composition and atmospheric deposition rates and composition were used to estimate the influence of immigration on bacterial community dynamics in two north temperate lakes.
  • Characterization of bacterial community dynamics using automated ribosomal intergenic spacer analysis suggested moderate overlap in composition between the lakes and atmospherically deposited cells.
  • However, taxa that appeared to be delivered by atmospheric deposition had a relatively minor influence on lake bacterial community dynamics.
  • The weak influence of immigrating bacterial taxa suggests that a species-sorting concept best describes aquatic bacterial metacommunity dynamics.
  • [MeSH-major] Bacteria / classification. Bacteria / isolation & purification. Biodiversity. Fresh Water / microbiology
  • [MeSH-minor] Cluster Analysis. DNA Fingerprinting. DNA, Bacterial / genetics. DNA, Ribosomal Spacer / genetics. Ecosystem. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040451.001).
  • [ISSN] 1462-2920
  • [Journal-full-title] Environmental microbiology
  • [ISO-abbreviation] Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


83. Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A, Tocewicz K, Pillay T, Clark S, Lordan JL, Schueler S, Fisher AJ, Dark JH, Gould FK, Corris PA: Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax; 2008 Aug;63(8):725-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lung transplantation is an important option to treat patients with advanced cystic fibrosis (CF) lung disease.
  • The outcomes of a large UK cohort of CF lung transplantation recipients is reported.
  • METHODS: Retrospective review of case notes and transplantation databases.
  • A diverse range of pathogens were encountered, including the Burkholderia cepacia complex (BCC).
  • Patients with BCC infection had poorer outcomes and represented the majority of those who had a septic death.
  • CONCLUSION: Lung transplantation is an important therapeutic option in patients with CF even in those with more complex microbiology.


84. Perrem K, Lynch A, Conneely M, Wahlberg H, Murphy G, Leader M, Kay E: The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol; 2007 Feb;38(2):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.
  • The incidence and aggressiveness of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma (SCC), in immunocompromised renal transplant recipients (RTRs) is dramatically higher (up to 100-fold) compared with the normal population.
  • SCC lesions are also predominant in RTRs, in contrast to the normal population where basal cell carcinoma is more common.
  • The mechanisms underlying this phenomenon are unknown, but effective treatments for these skin tumors would have a significant impact upon morbidity in this group of patients.
  • The fundamental role of telomeres and telomerase in the development of most human cancers, including melanoma, is well established, but very few reports have assessed their function during the onset of nonmelanoma skin cancer.
  • To assess whether telomere maintenance plays any role in the increased incidence of SCC in renal transplant patients, we analyzed both the telomere lengths and telomerase expression levels in 44 SCCs and 22 Bowen's disease (BD) samples (carcinoma in situ) from RTRs and nontransplant patients.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Squamous Cell / etiology. Kidney Transplantation / adverse effects. Skin Neoplasms / etiology. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line. HeLa Cells. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Telomerase / biosynthesis


85. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • BCC is mainly located on sun exposed sites, being head and neck the areas of more incidence; although nose, eyelids and periorbitary tissue are unfavorable due to cosmetic results that BCC involves.
  • Mohs' micrographic surgery is the standard treatment for all non-melanoma skin cancer.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


86. Feizy V, Toosi S: Relation of basal cell carcinoma to hair dye use. J Am Acad Dermatol; 2009 Sep;61(3):532-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of basal cell carcinoma to hair dye use.
  • [MeSH-major] Hair Dyes / adverse effects. Neoplasms, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700022.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hair Dyes
  •  go-up   go-down


87. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P, Hereditary Breast Cancer Clinical Study Group: Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol; 2006 May;7(5):402-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
  • BACKGROUND: Screening mammography is associated with a small dose of radiation to the breast, and women with increased genetic risk might be particularly sensitive to the DNA-damaging effects of ionising radiation.
  • We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
  • METHODS: We identified 1600 cases of breast cancer and 1600 controls without breast cancer who were matched for BRCA mutation, date of birth (within 1 year), and country of residence from an international registry of BRCA1 and BRCA2 mutation carriers.
  • RESULTS: We found no association between ever having screening mammography and risk of breast cancer (odds ratio [OR] 1.03 [95% CI 0.85-1.25], adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy).
  • INTERPRETATION: These findings do not lend support to the idea that exposure to ionising radiation through routine screening mammography contributes substantially to the burden of breast cancer in BRCA1 and BRCA2 mutation carriers.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / epidemiology. Mammography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Mass Screening. Middle Aged. Mutation. Risk Factors


88. Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, Dunning AM: Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev; 2006 Apr;15(4):675-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach.
  • Association studies on susceptibility to breast cancer using single nucleotide polymorphisms (SNP) in the progesterone receptor (PGR) gene have been previously published, but the results have been inconclusive.
  • We used a comprehensive SNP-tagging approach to search for low-penetrance susceptibility alleles in a study of up to 4,647 cases and 4,564 controls, in a two-stage study design.
  • We identified seven tagging SNPs using genotype data from the National Institute of Environmental Health Sciences (NIEHS) Environmental Genome Project and typed these, and an additional three SNPs, in 2,345 breast cancer cases and 2,284 controls (set 1).
  • After both stages, only one SNP was significantly associated with an increased risk of breast cancer - the PGR-12 (rs1042638) V660L valine to leucine polymorphism [VL heterozygotes (odds ratio, 1.13; 95% confidence interval, 1.03-1.24) and the LL homozygotes (odds ratio, 1.30; 95% confidence interval, 0.98-1.73), P(het) = 0.008, P(trend) = 0.002].
  • We conclude that the 660L allele may be associated with a moderately increased risk of breast cancer, but that other common SNPs in the PGR gene are unlikely to be associated with a substantial risk of breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide / genetics. Receptors, Progesterone / genetics. Sequence Tagged Sites
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gene Frequency. Great Britain. Haplotypes. Humans. Linkage Disequilibrium. Middle Aged. Risk. Valine / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Valine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614108.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Progesterone; HG18B9YRS7 / Valine
  •  go-up   go-down


89. De-Domingo B, González F, Lorenzo P: [Gorlin syndrome (nevoid basal cell carcinoma syndrome)]. Arch Soc Esp Oftalmol; 2008 May;83(5):321-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gorlin syndrome (nevoid basal cell carcinoma syndrome)].
  • [Transliterated title] Síndrome de Gorlin (síndrome nevoide basocelular).
  • CLINICAL CASE: A 77 year-old male patient with Parkinson's disease and senile dementia had many facial basal cell carcinomas and an ectropion of the left eye.
  • DISCUSSION: Gorlin syndrome is an autosomal dominant condition characterized by basal cell carcinomas, and skeletal and neurological anomalies.
  • The presence of multiple basal cell carcinomas on the eyelids in a child or in a young patient should alert ophthalmologists to the possibility of this syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Eyelid Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464182.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


91. Snipes CJ, Sniezek PJ, Walling HW: Basal cell carcinoma responding to systemic 5-fluorouracil. J Am Acad Dermatol; 2006 Jun;54(6):1104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma responding to systemic 5-fluorouracil.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Basal Cell / drug therapy. Fluorouracil / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713484.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Kaeb S, Landthaler M, Hohenleutner U: Confocal laser scanning microscopy--evaluation of native tissue sections in micrographic surgery. Lasers Med Sci; 2009 Sep;24(5):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micrographic surgery is mainly used for excising basal cell carcinomas in high-risk body sites.
  • We examined the margins of 52 excised basal cell carcinomas by means of CM, and compared the results to conventional histological findings.
  • The morphologic features of tumors seen in CM corresponded well to conventional light microscopy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Microscopy, Confocal / methods. Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Cutan Med Surg. 2007 Jan-Feb;11(1):19-30 [17274935.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • (PMID = 19277819.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Pérez-Brocal V, Latorre A, Gil R, Moya A: Comparative analysis of two genomic regions among four strains of Buchnera aphidicola, primary endosymbiont of aphids. Gene; 2005 Jan 17;345(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary analysis of two selected genomic regions of Buchnera aphidicola BCc, the primary endosymbiont of the cedar aphid Cinara cedri, has revealed a number of interesting features when compared with the corresponding homologous regions of the three B. aphidicola genomes previously sequenced, that are associated with different aphid species.
  • Both regions exhibit a significant reduction in length and gene number in B. aphidicola BCc, as it could be expected since it possess the smallest bacterial genome.
  • In both regions, G+C content is about 4% lower in BCc than in the other B. aphidicola strains.

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716086.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY744381/ AY744382
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Intergenic
  •  go-up   go-down


94. Gupta S, Takebe N, Lorusso P: Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol; 2010 Jul;2(4):237-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the Hedgehog pathway in cancer.
  • The Hedgehog (Hh) pathway is a major regulator of many fundamental processes in vertebrate embryonic development including stem cell maintenance, cell differentiation, tissue polarity and cell proliferation.
  • Constitutive activation of the Hh pathway leading to tumorigenesis is seen in basal cell carcinomas and medulloblastoma.
  • A variety of other human cancers, including brain, gastrointestinal, lung, breast and prostate cancers, also demonstrate inappropriate activation of this pathway.
  • This pathway has also been shown to regulate proliferation of cancer stem cells and to increase tumor invasiveness.
  • The discovery and synthesis of specific Hh pathway inhibitors have significant clinical implications in novel cancer therapeutics.
  • Initial clinical trials in basal cell carcinoma and treatment of select patients with medulloblastoma have shown good efficacy and safety.
  • We review the molecular basis of Hh signaling, the current understanding of pathway activation in different types of human cancers and we discuss the clinical development of Hh pathway inhibitors in human cancer therapy.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):196-8 [12734424.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1018-21 [16136078.001]
  • [Cites] Trends Mol Med. 2005 Dec;11(12):537-45 [16290230.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):748-57 [16339184.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] J Cell Sci. 2007 Jan 1;120(Pt 1):3-6 [17182898.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5674-9 [17353904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 [17494766.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Science. 1996 Oct 11;274(5285):255-9 [8824192.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):353-6 [8896571.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):357-60 [8896572.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Cell. 1997 Jul 25;90(2):193-6 [9244291.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Neuron. 1998 Dec;21(6):1243-57 [9883719.001]
  • [Cites] J Anat. 1971 Dec;110(Pt 3):507 [5004470.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5428-37 [14500378.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Nature. 2003 Nov 6;426(6962):83-7 [14603322.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3961-70 [15132968.001]
  • [Cites] Eur J Dermatol. 2004 Mar-Apr;14(2):96-102 [15196999.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Development. 2005 Jan;132(2):335-44 [15604099.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11325-30 [16061793.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Cell Cycle. 2007 Oct 15;6(20):2458-63 [17726373.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2241-9 [18381430.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):238-49 [18772113.001]
  • [Cites] Genes Dev. 2008 Sep 15;22(18):2454-72 [18794343.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):5995-6004 [18829478.001]
  • [Cites] Mol Cancer Res. 2008 Dec;6(12):1928-36 [19074837.001]
  • [Cites] Dev Cell. 2008 Dec;15(6):801-12 [19081070.001]
  • [Cites] Genes Dev. 2009 Jan 1;23(1):24-36 [19136624.001]
  • [Cites] Nat Chem Biol. 2009 Mar;5(3):154-6 [19151731.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):776-9 [19169242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] Trends Pharmacol Sci. 2009 Jun;30(6):303-12 [19443052.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6007-10 [19638582.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1202-5 [19726764.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):445-8 [10226030.001]
  • [Cites] Neuron. 1999 Aug;23(4):713-24 [10482238.001]
  • [Cites] Ann N Y Acad Sci. 1999 Sep 14;883:196-202 [10586245.001]
  • [Cites] Cell. 2000 Jan 21;100(2):185-8 [10660040.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):216-7 [10700170.001]
  • [Cites] Nature. 2001 Mar 29;410(6828):599-604 [11279500.001]
  • [Cites] Annu Rev Neurosci. 2001;24:385-428 [11283316.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Development. 2002 Feb;129(4):843-51 [11861468.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • (PMID = 21789137.001).
  • [ISSN] 1758-8359
  • [Journal-full-title] Therapeutic advances in medical oncology
  • [ISO-abbreviation] Ther Adv Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3126020
  • [Keywords] NOTNLM ; GDC-0449 / Hedgehog / basal cell carcinoma / cancer stem cells / medulloblastoma
  •  go-up   go-down


95. Aka JA, Mazumdar M, Chen CQ, Poirier D, Lin SX: 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol; 2010 Apr;24(4):832-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
  • The active estrogen estradiol (E2) stimulates breast cancer cell (BCC) growth, whereas the androgen dihydrotestosterone (DHT) has shown an antiproliferative effect.
  • However, the direct roles of 17beta-HSD1 in sex-hormone regulation and BCC proliferation have not been completely established.
  • Here, we show that 17beta-HSD1 inhibition suppresses DHT catabolism by 19%, whereas knockdown of the gene expression increases the concentration of DHT by 41% in the T47D BCC line.
  • The 17beta-HSD1/DHT complex crystal structure reveals that DHT binds in both normal and reverse modes, but the latter mode leading to O3 reduction is preferred with stronger interactions.
  • Using RNA interference and an inhibitor of 17beta-HSD1, we demonstrate that 17beta-HSD1 expression is negatively correlated to DHT levels in BCC but positively correlated to estrone reduction, E2 levels, and cell proliferation.
  • Thus, 17beta-HSD1 up-regulates BCC growth by a dual action on estradiol synthesis and DHT inactivation.
  • We have further demonstrated that 17beta-HSD1 can enhance the E2-induced expression of the endogenous estrogen-responsive gene pS2, providing an important information regarding the modulation of the estrogen responsiveness by 17beta-HSD1 that may also contribute to BCC growth.
  • These results strongly support the rationale for inhibiting 17beta-HSD1 in breast cancer therapy to eliminate estrogen activation via the sulfatase pathway while avoiding the deprivation of DHT.
  • [MeSH-major] Breast Neoplasms / metabolism. Dihydrotestosterone / metabolism. Estradiol / metabolism. Estradiol Dehydrogenases / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line. Cell Line, Tumor. Cell Proliferation. Gas Chromatography-Mass Spectrometry. Humans. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1995 Dec;55(5-6):525-32 [8547177.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10600-7 [17975005.001]
  • [Cites] Maturitas. 2007 May 20;57(1):47-9 [17386984.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Oct 1;232(1):78-85 [18640140.001]
  • [Cites] Science. 1978 Feb 17;199(4330):787-8 [622569.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):600-4 [8938141.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1535-65 [11581496.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103 [10819508.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):246-9 [16490301.001]
  • [Cites] Horm Res. 2003;60 Suppl 3:50 [14671396.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43 [15172700.001]
  • [Cites] Steroids. 2007 Dec;72(14):914-22 [17854852.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jul;59(1):29-33 [6725522.001]
  • [Cites] FASEB J. 2003 Feb;17(2):274-6 [12490543.001]
  • [Cites] Nat Struct Biol. 1996 Aug;3(8):665-8 [8756321.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Dec;43(7):599-607 [1472451.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Antimicrob Agents Chemother. 2005 May;49(5):1915-26 [15855514.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):788-90 [12679933.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 25;301(1-2):183-90 [19038308.001]
  • [Cites] Bioorg Med Chem. 2008 Feb 15;16(4):1849-60 [18035543.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(2):289-96 [18521740.001]
  • [Cites] J Steroid Biochem. 1989;34(1-6):155-63 [2560511.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36 [15860265.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):1-15 [17631997.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Jan;88(1):37-51 [15026082.001]
  • [Cites] Toxicol Sci. 2008 Oct;105(2):303-11 [18644836.001]
  • [Cites] J Immunol Methods. 1994 Sep 14;174(1-2):311-20 [8083535.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):701-20 [16322318.001]
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):249-89 [14758095.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10784-95 [14672942.001]
  • [Cites] Breast Cancer Res. 2007;9(6):R77 [17986353.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16778-85 [14966133.001]
  • [Cites] Structure. 1995 May 15;3(5):503-13 [7663947.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):71-6 [11165013.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3131-5 [2039992.001]
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16182-7 [1322895.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):793-810 [15171713.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 2;344(2):540-6 [16630558.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):2010-20 [11682630.001]
  • [Cites] Endocrinology. 1988 Sep;123(3):1281-7 [2969800.001]
  • [Cites] Biotechniques. 2005 Feb;38(2):287-93 [15727135.001]
  • [Cites] J Enzyme Inhib Med Chem. 2005 Apr;20(2):153-63 [15968820.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Dec;67(4):657-85 [14665679.001]
  • [Cites] J Steroid Biochem. 1986 Nov;25(5B):799-802 [3027457.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):1931-40 [18183589.001]
  • [Cites] Reprod Biol Endocrinol. 2006 Oct 06;4:51 [17026757.001]
  • [Cites] Structure. 1996 Aug 15;4(8):905-15 [8805577.001]
  • [Cites] Biotechniques. 1994 Feb;16(2):282-4, 286-8 [7514006.001]
  • [Cites] Endocrinology. 1993 Jan;132(1):179-85 [8380373.001]
  • [Cites] J Mol Biol. 1993 Nov 5;234(1):242-4 [8230203.001]
  • [Cites] Bioorg Med Chem. 1996 Oct;4(10):1617-28 [8931931.001]
  • [Cites] Breast Cancer Res Treat. 1995 May;34(2):139-46 [7647331.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2890-901 [10733592.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):875-84 [16954436.001]
  • (PMID = 20172961.001).
  • [ISSN] 1944-9917
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP57892
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 08J2K08A3Y / Dihydrotestosterone; 4TI98Z838E / Estradiol; EC 1.1.1.62 / Estradiol Dehydrogenases; EC 1.1.1.62 / HSD17B1 protein, human
  •  go-up   go-down


96. Gambichler T, Skrygan M, Huyn J, Bechara FG, Sand M, Altmeyer P, Kreuter A: Pattern of mRNA expression of beta-defensins in basal cell carcinoma. BMC Cancer; 2006;6:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of mRNA expression of beta-defensins in basal cell carcinoma.
  • BACKGROUND: Although the human beta-defensins hBDs today seem to have diverse functional activities in innate antimicrobial immunity, a few reports also indicated an altered expression of these antimicrobial peptides (AMPs) in tissues of cancers such as oral squamous cell carcinoma.
  • The present work was aimed on the study of hBD gene expression in basal cell carcinoma (BCC) which is the most common cancer in humans.
  • METHODS: Twenty-two non-ulcerated BCCs (12 nodular type, 10 superficial type) have been analysed for the presence of hBD (1-3) mRNA by quantitative real-time RT-PCR.
  • As controls, non-lesional skin specimens of BCC patients as well as samples of healthy subjects were assessed by RT-PCR.
  • RESULTS: hBD-1 levels in healthy controls and non-lesional skin of BCC patients were significantly (P < 0.05) higher than the levels observed in tumour tissue.
  • Moreover, BCCs showed significantly (P < 0.05) increased mRNA expression of hBD-2 as compared to controls.
  • The mRNA expression of hBDs (1-3) found in nodular and superficial BCCs did not significantly (P > 0.05) differ.
  • CONCLUSION: The gene expression patterns of hBD-1 and hBD-2 are for the first time shown to be significantly altered in non-ulcerated BCCs as compared to intra-individual and inter-individual controls, respectively.
  • The present findings may indicate that beside the antimicrobial activity of AMPs, hBDs may also play a role in the pathogenesis of BCC.
  • However, functional and immunohistological studies investigating hBDs in patients with BCC are needed to confirm our data.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. beta-Defensins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1125-7 [10810407.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1275-8 [17107401.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):79-84 [12680197.001]
  • [Cites] Lab Invest. 2003 Apr;83(4):501-5 [12695553.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7515-9 [14612553.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4629-33 [14981906.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):181-6 [15202832.001]
  • [Cites] Eur J Med Res. 1998 Jul 20;3(7):315-23 [9682027.001]
  • [Cites] Cancer Lett. 1999 Aug 23;143(1):37-43 [10465335.001]
  • [Cites] Science. 1999 Oct 15;286(5439):525-8 [10521347.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):328-30 [15627069.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4051-7 [15736451.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):381-90; quiz 391-2 [15761415.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Skin Res Technol. 2005 Aug;11(3):196-200 [15998331.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1163-73 [16354186.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • (PMID = 16796735.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC1538617
  •  go-up   go-down


97. Mladek BM, Gottwald D, Kahl G, Neumann M, Likos CN: Formation of polymorphic cluster phases for a class of models of purely repulsive soft spheres. Phys Rev Lett; 2006 Feb 3;96(4):045701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clustering is accompanied by polymorphic bcc-fcc transitions, with fcc being the stable phase at high densities.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Phys Rev Lett. 2006 Jul 7;97(1):019901
  • (PMID = 16486844.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Soufir N, Gerard B, Portela M, Brice A, Liboutet M, Saiag P, Descamps V, Kerob D, Wolkenstein P, Gorin I, Lebbe C, Dupin N, Crickx B, Basset-Seguin N, Grandchamp B: PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer; 2006 Aug 21;95(4):548-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study.
  • The patched (PTCH) mutation rate in nevoid basal cell carcinoma syndrome (NBCCS) reported in various studies ranges from 40 to 80%.
  • However, few studies have investigated the role of PTCH in clinical conditions suggesting an inherited predisposition to basal cell carcinoma (BCC), although it has been suggested that PTCH polymorphisms could predispose to multiple BCC (MBCC).
  • In this study, we therefore performed an exhaustive analysis of PTCH (mutations detection and deletion analysis) in 17 patients with the full complement of criteria for NBCCS (14 sporadic and three familial cases), and in 48 patients suspected of having a genetic predisposition to BCC (MBCC and/or age at diagnosis < or =40 years and/or familial BCC).
  • In other clinical situations that suggest genetic predisposition to BCC, germline mutations of PTCH are not common.
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Carcinoma, Basal Cell / genetics. Gene Deletion. Mutation. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] France. Genetic Predisposition to Disease. Humans. Microsatellite Repeats

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No To Hattatsu. 2000 Jan;32(1):49-55 [10655752.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Environ Mol Mutagen. 2004;44(5):469-76 [15534865.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):868-73 [15888139.001]
  • [Cites] Hum Mutat. 2005 Sep;26(3):283 [16088933.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):892-7 [12373605.001]
  • [Cites] Eur J Pediatr. 2003 Feb;162(2):100-3 [12548386.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2967-71 [12771948.001]
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Am J Med Genet A. 2004 Jan 15;124A(2):179-91 [14699618.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):417-22 [8755929.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4599-601 [8840969.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):21-6 [8981943.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1798-803 [9581815.001]
  • [Cites] Hum Genet. 2001 Jul;109(1):121-4 [11479744.001]
  • (PMID = 16909134.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Other-IDs] NLM/ PMC2360669
  •  go-up   go-down


99. Sugano DM, Lucci LM, Avila MP, Rehder JR, Pettinati J: [Eyelid trichoepithelioma--report of 2 cases]. Arq Bras Oftalmol; 2005 Jan-Feb;68(1):136-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eyelid trichoepithelioma--report of 2 cases].
  • [Transliterated title] Tricoepitelioma palpebral--relato de 2 casos.
  • Trichoepithelioma is a benign skin tumor and is most commonly found on the face, however, there are few reports about its occurrence on the eyelids.
  • The purpose of this paper is to report two cases of solitary trichoepithelioma on the eyelid, their histopathology and treatment.
  • This lesion should be considered when a single solid nodule on the face appears, and can be differentiated from basal-cell carcinoma.
  • [MeSH-major] Eyelid Neoplasms / pathology. Neoplasms, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824820.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


100. Wang X, Wu X, Liang Z, Huang Y, Fenech M, Xue J: A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan. Mutagenesis; 2006 Jan;21(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan.
  • We hypothesized that the genomic response to folate deficiency might be different between breast cancer cases and healthy subjects.
  • To test this hypothesis, we performed a comprehensive study on the genotoxic and cytotoxic effects of in vitro folic acid (FA) deficiency on primary human lymphocytes from 19 breast cancer patients and 20 age-matched healthy females from Yunnan, China using the cytokinesis-block micronucleus assay.
  • The results showed that 30 nM FA was associated with increased frequencies of micronucleated binucleated cell (MNed BNC), nucleoplasmic bridges (NPB), nuclear buds (BUD), apoptosis (APO) and necrosis (NEC) relative to 120 and 240 nM FA (P<0.001) in lymphocytes of case and control groups in vitro, however there were no significant differences between the 120 and 240 nM FA within each sampling group.
  • The case group showed significantly higher frequencies of MNed BNC than control at 120 and 240 nM FA (P<0.05-0.001) but not at 30 nM FA (P=0.052).
  • NEC was significantly higher in breast cancer group than control at all concentrations of FA (P<0.005).
  • FA concentration explained 60, 39, 39, 52 and 71% of the variance of MNed BNC, NPB, BUD, APO and NEC, respectively compared with breast cancer status which only explained 6 and 7% of the variance of MNed BNC and NEC(Two way ANOVA, P<0.0001).
  • Difference of difference analysis showed that breast cancer cases were not abnormally sensitive to the genome-damaging effect of folate deficiency.
  • We concluded that (i) increased concentrations of FA abolished the genome-damaging effect of FA deficiency in lymphocytes of both breast cancer patients and controls to a similar extent and (ii) FA concentration is much more important than breast cancer status in determining genomic instability and cell death.
  • [MeSH-major] Breast Neoplasms. Folic Acid Deficiency / metabolism. Genomic Instability. Lymphocytes / drug effects
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Breast / metabolism. Breast / pathology. Case-Control Studies. China / epidemiology. Cytokinesis / drug effects. Female. Folic Acid / pharmacology. Humans. Micronuclei, Chromosome-Defective. Micronucleus Tests. Middle Aged. Necrosis. Population Groups

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339195.001).
  • [ISSN] 0267-8357
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down






Advertisement